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Abstract
Current ex vivo models of thrombosis either fail to accurately recreate the hemodynamics and focal
nature of injuries commonly found throughout the vasculature or require excess amounts of material.
Development of a novel microfluidic thrombosis model has allowed for the measurement of thrombus
stability of platelet aggregates formed on collagen from a single non-lethal murine blood draw. It was
observed that platelet accumulation exhibits a biphasic behavior, with maximum accumulation at an
average wall shear rate of 400 1/sec, with engagement of alpha2beta1 integrin a mandatory factor due to
complete loss of adhesion in blood from a knockout animal. It was found that PAR4 stimulation of preformed thrombi increased aggregate stability by 50%. Subsequent device designs were made to
simultaneously measure platelet accumulation on collagen of eight samples under independent bulk
pharmacological intervention. This provided a platform for rapidly and repeatable assessing the potency
of receptor antagonists under relevant flow conditions with half-maximal inhibitor concentrations (P2Y1
inhibitor MRS 2179 IC50=0.23 uM, P2Y12 inhibitor 2-MeSAMP IC50=2.56 uM) comparable to published
data, while an enzyme commonly used failed to have any effect due to transport limitations. Finally,
investigation into the effects of tissue factor initiated coagulation in addition to collagen-induced platelet
accumulation and activation revealed a number of technical hurdles required for further experimentation.
The use of custom functional liposomes as linkers for surface immobilization provides a platform for
careful titration of active tissue factor onto a surface at high densities (up to 35 active tissue factor
molecules per um^2) for illumination into the role and extent of thrombin and fibrin formation during
hemostatic injury. Additionally, geometries akin to late stage atherosclerotic vessels open the possibility
of shear history affecting the growth and stability of platelet thrombi formed on collagen. Investigation of
bulk phase shear-mediated von Willebrand Factor conformational changes could illuminate both
mechanistic processes involved in pathological thrombosis and provide a basis for new biomarkers for
patients at risk for a catastrophic thrombotic event.
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ABSTRACT
MICROFLUIDIC FOCAL INJURY MODELS OF THROMBOSIS AND
HEMOSTASIS
Sean Francis Maloney
Scott L. Diamond
Current ex vivo models of thrombosis either fail to accurately recreate the hemodynamics and focal nature of injuries commonly found throughout the vasculature or
require excess amounts of material. Development of a novel microfluidic thrombosis
model has allowed for the measurement of thrombus stability of platelet aggregates
formed on collagen from a single non-lethal murine blood draw. It was observed that
platelet accumulation exhibits a biphasic behavior, with maximum accumulation at
an average wall shear rate of 400 sec−1 , with engagement of α2 β1 integrin a mandatory factor due to complete loss of adhesion in blood from a knockout animal. It was
found that PAR4 stimulation of pre-formed thrombi increased aggregate stability by
50%. Subsequent device designs were made to simultaneously measure platelet accumulation on collagen of eight samples under independent bulk pharmacological intervention. This provided a platform for rapidly and repeatable assessing the potency of
receptor antagonists under relevant flow conditions with half-maximal inhibitor concentrations (P2Y1 inhibitor MRS 2179 IC50 = 0.23 µM, P2Y12 inhibitor 2-MeSAMP
IC50 = 2.56 µM) comparable to published data, while an enzyme commonly used
failed to have any effect due to transport limitations. Finally, investigation into the
effects of tissue factor initiated coagulation in addition to collagen-induced platelet
accumulation and activation revealed a number of technical hurdles required for further experimentation. The use of custom functional liposomes as linkers for surface
immobilization provides a platform for careful titration of active tissue factor onto
a surface at high densities (up to 35 active tissue factor molecules per µm2 ) for
illumination into the role and extent of thrombin and fibrin formation during hemostatic injury. Additionally, geometries akin to late stage atherosclerotic vessels open
v

the possibility of shear history affecting the growth and stability of platelet thrombi
formed on collagen. Investigation of bulk phase shear-mediated von Willebrand Factor conformational changes could illuminate both mechanistic processes involved in
pathological thrombosis and provide a basis for new biomarkers for patients at risk
for a catastrophic thrombotic event.
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Chapter 1
Introduction
1.1
1.1.1

Background
Blood, the vasculature, and hemostasis

The development of a high-pressure closed circulatory system necessarily required the
adaptation of mechanisms to rapidly stop blood loss upon injury while maintaining
bulk fluidity during homoeostatic periods. The delicate balance is dependent on both
the removal of procoagulant species from the circulation and the active passivization.
Whole blood consists of numerous cellular components suspended in a milieu of
dissolved gases, ionic species, molecules, and proteins. The cellular fraction of blood
is significant, red blood cells (RBCs) comprise between 35 and 50 % of blood volume,
which has implications on both blood rheology [65] hemostatic processes [1, 108].
While RBCs make up a majority of the cellular component of blood, nucleated cells
including, but not limited to, neutrophis, eiosinophils, monocytes, and macrophages
are critical components of immunity and host defense. The final major cellular class
found in blood is platelets. These small anuclear cells are the second most plentiful,
with normal circulation levels between 150 and 400 ×109 cells per L. Platelets are
small irregularly shaped discoid cells between 2 and 4 µm in diameter. They are the
1

major cellular player in hemostasis and thrombosis, and are conserved throughout
the Class Mammalia, though nucleated thrombocytes are found throughout other
classes of animals [66].
The second half of the hemostasis and thrombosis process is a series of enzymatically catalyzed proteolysis reactions that is referred to as the coagulation cascade, as
shown in Figure 1.1. These proteins are found a wide range of levels in the circulation, most as inactive zymogens, which are, upon proteolytic cleavage, converted into
either active enzymes or cofactors. As is indicated by Figure 1.1, there are numerous
feed-back and feed-forward processes that serve to both amplify and dampen the
response of the coagulation cascade’s most functional product, the enzyme thrombin (IIa). Thrombin acts as the nexus of the coagulation cascade by both rapidly
feeding back to accelerate its formation and by initiating events that will lead to its
inactivation and subsequent clearance from the circulation.
A closed vascular system is, at the most basic level, a pump, series of pipes, and
mass contactors. The heart acts as the pump, which moves the process fluid, blood,
through the arteries and the vasculature system through series of smaller vessels to
tissues throughout the body where dissolved gases, ions, molecules, and proteins are
exchanged. The system operates under a positive pressure, i.e. blood is forced from
a high pressure (immediately exiting the left ventricle into the aorta) down pressure
gradients throughout the vasculature , recollected into the right atrium via the venous
system, all the while at pressures greater than atmospheric. Upon return to the heart,
the right ventricle pumps the blood through the lungs where gaseous species are
exchange with inhaled air, after which blood returns through the left atrium, where
it is cycled back into the left ventricle for circulation back to the body. The blood
vessels that run throughout the body are lined with a monolayer of endothelial cells
which serve numerous functions both in hemostasis and other biological processes.
Beneath the endothelial cells are subendothelial matrix proteins, including collagen,
vitronectin, and laminin. The endothelial cells and subendothelial matrix comprise
2

Figure 1.1: The enzymatic reactions of the coagulation cascade (courtesy of Bill
Denney).
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the intima of the blood vessel. Beneath this layer is the media, comprising of smooth
muscle cells which control vaso-constriction and -dilation to regulate blood pressure
and flow rate to different regions of the body. The final layer of vessel composition
is the adventitia, which is dominated by connective tissue and fat to insulate and
provide structural integrity to the overall system.
In order to maintain the fluidity of blood under physiological conditions, the endothelial cell layer performs a number of important functions. Protein expressed constitutively on the luminal side are active nucleotide phosphatases (CD39) which act
by hydrolyzing adenosine diphosphate (ADP), a platelet agonist, to its monophosphorolated form which is not recognized by platelet receptors. Also, endothelial cells
synthesize nitric oxide and prostacyclin (PGI2 ) which serve to keep platelets in a
quiescent state by increasing intracellular levels of cyclic adenosine monophosphate
(cAMP) inside the platelets. Cyclic AMP acts on calcium pumps within the platelet
which actively move calcium ions from the cytoplasm into either dense tubular storage or into the extracellular milieu. In addition to serving biochemical functions,
endothelial cells serve as a physical barrier to keep blood cells, specifically platelets,
from interacting with the subendothelial matrix. Platelet are specially adept at
quickly recognizing sites of injury, adhering and activating to quell blood loss and
maintain vascular integrity.

1.1.2

Platelets

Platelets have evolved to fit a very unique niche within the context of a closed, highpressure vascular system. The loss of sufficient blood flow to organs due to either
excessive blood loss through a failure of vessel integrity (hemorrhage) or blockage of
flow through the vessel (ischemia) results in tissue death if not rectified. Platelets
are the primary cell type involved with keeping the balance between these two states
when blood vessels are breached due to injury and are ideal for this purpose for
several reasons. Firstly, platelets are generated by thrombopoiesis, by which they are
4

shed from mature megakaryocytes, which are found in the bone marrow throughout
the body. As a result, platelets contain mRNA and other translational machinery
found throughout the cytoplasm of megakaryocytes, enabling them to synthesize
new proteins upon stimulation, but lack DNA and the transcriptional proteins that
would be required for generating new messages.
Platelets express a range of surface proteins that are critical for proper function as hemostatic agents. The most well studied platelet surface proteins fall into
three categories: integrins, glycoproteins, and G-protein coupled receptors. Integrins
are heterodimeric proteins consisting of an α and β subunit. These receptors are
expressed in a variety of levels on both the apical and luminal side of the plasma
membrane. Upon platelet activation, membrane sections are flipped and granules
released, causing the copy number and types of membrane proteins on the platelet
surface to greatly change. Subsequently, throughout the platelet activation process,
some surface proteins are shed from the surface while others are internalized upon
ligand binding or other signaling events. The exposure of certain proteins is accompanied by exposure of different types of lipids on the platelet surface, specifically the
negatively charged phospholipid phosphatidylserine (PS). This negative lipid surface
is crucial for the proper assembly and proteolytic cleavage of several enzymes in the
coagulation cascade (as shown in the gray boxes in Figure 1.1). While circulating
in a quiescent state, platelet integrins, mainly αIIb β3 , α2 β1 , and αV β3 , are in an
inactive or low-affinity state. Upon platelet activation via an independent route, the
integrins undergo a conformational change, setting the ligand binding region into
a high-affinity state. This ‘inside-out’ signaling allows platelets to interact modularly with species that are found ubiquitously throughout the blood, like the soluble
protein fibrinogen. Complementary, upon ligand binding, additional changes are induced on the stalk and cytoplasmic tail of the integrin proteins, allowing for both
intracellular signaling and scaffold protein binding as an ‘outside-in’ signal. Glycoproteins are an important class of platelet surface molecules that, like integrins,
5

Figure 1.2: Different phases of platelet activation: I. Initial adhesion (A), II. Pseduopod extension and membrane ruffling (C), III. Granule fusion and membrane
peeling (B), IV. Compression and collapse (A) V. Membrane disintegration leaving
only microtubules and cytoskeletal proteins (B).
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function both as adhesion molecules and signaling molecules. Glycoproteins are in
a constitutively active confirmation, and are post-translationally modified with numerous sugar groups, hence the nomenclature. The two glycoproteins that are active
in hemostatic processes on the platelet surface are glycoprotein VI (GPVI) and the
glycoprotein Ib-IX-V complex (GPIb-IX-V).
G-protein coupled receptors, or GPCRs, are transmembrane proteins that present
extracellular ligand binding sites and are coupled to one or more a subtype of Gprotein that activates a signaling cascade upon ligand binding. Among the most
studied GPCRs expressed on the platelet surface are the purinergic receptors, P2Y1
P2Y12 , and P2X1 , the thromboxane receptor (TP) and the protease activated receptors, PAR1 and PAR4. While the specifics of G-protein signaling are complicated and still under intense research, their importance in platelet signaling are
undoubted. The intrinsic regulation of G-protein signaling via signaling molecules
such as kinases and phosphatases within the platelet allows for very complex response behavior. Coupling to feed-forward and feed-back mechanisms allow for a
full range from rapid-on/rapid-off signals for fast responses to long, sustained signals
depending on the molecules involved. The output of these signaling pathways result
in a wide range of signals, including inside-out integrin activation, calcium release,
granule fusion. The physical manifestations of platelet activation can be seen in
Figure 1.2.

1.1.3

Coagulation

The coagulation cascade describes the collection of proteolytic processes as shown
in Figure 1.1. The large interaction web between numerous zymogens, cofactors,
enzymes, and reactive surfaces are frequently broken down into three pathways:
intrinsic, extrinsic, and common, as shown in Figure 1.3. The role of the contact
pathway in thrombin formation in vivo is currently under investigation [109], but
the classical view of in vivo thrombin generation is tissue factor initiated via the
7

Figure 1.3: Breakdown of the coagulation cascade into the intrinsic (red), extrinsic
(blue), and common (green) pathways.
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extrinsic pathway. Upon endothelial cell disruption during an injury, tissue factor
that is exposed to flowing blood. Small circulating levels of activated Factor VII
(FVIIa) bind to the exposed tissue factor and initiate the cascade. There are also
a number of other sources of tissue factor, such as monocytes, microparticles, and
platelets. Upon binding of FVIIa to tissue factor, small amounts of activated Factor
X (FXa) are formed, which can activate Factor V to FVa. The assembly of Factor
Xa and Va on a negatively charged phospholipid surface is what is referred to as the
prothrombinase complex, the coenzyme that converts prothrombin into thrombin.
Thrombin is the central enzyme in the coagulation cascade and an important link
between coagulation, platelets, and the rest of the vascular system, with its involvement in many of the coagulation reactions highlighted in Figure 1.4. A potent serine
protease, thrombin is able to cleave and activate other proteases as well as a number of protease activated receptors, or PARs, on the surface of platelets, endothelial
cells, neutrophils and other cells associated with vascular integrity. Thrombin serves
to rapidly increase its product by feeding back in the common pathway (the green
section of Figure 1.4), while also rapidly being deactivated by the serine protease
inhibitor, or SERPIN, antithrombin III (ATIII), which is present at high (2.3 µM)
concentrations in the circulating plasma. This kinetic competition of feedback and
inhibition leads to a very complex and finely regulated system, which is advantageous
for such a potent end-product such as thrombin.
Ultimately, thrombin serves as the major component that interacts with both
the coagulation cascade and platelets. PARs on the platelet surface respond to
thrombin activity, while platelets serves as the major source of negatively charged
phospholipid support for coagulation complex assembly and proteolysis. It is this
tight integration of the two systems that lends much of the complexity to many of
the model systems used to investigate the biology and function of hemostasis and
thrombosis and general.
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Figure 1.4: The role of thrombin, the central enzyme in the coagulation cascade, is
highlighted in its many feed-back and feed-forward roles.

1.2

Motivation

The motivation behind this work is to develop and use new tools to study phenomena in thrombosis and hemostasis. By using well established soft-lithographic
techniques to generate a set of microfluidic devices to pattern and then perfuse solutions over a glass substrate. The ability to use small volumes of materials to create
focalized models of thrombosis for real-time and post-hoc analysis is targeted to a
technology gap currently facing researchers in both basic science and clinical applications of platelet biology and coagulation biochemistry. Since blood is necessarily
under flow in closed, high-pressure circulatory systems, models for injuries that can
capture the hemodynamics and flow characteristics are more realistic and offer better opportunities to accurately describe the phenomena which occur in vivo. There
are a number of technologies that are currently used to investigate hemostatic processes while under flow ex vivo, such as parallel plate flow chambers, capillary flow
chambers, and cone-and-plate viscometers; however, each has their shortfall in terms
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of material requirement, patterning capability, or realistic hemodynamics. By coupling micropatterning techniques with flexible channel designs, microfluidics allows
for realistic, spatially confined injury mimetics to be formed under controlled flow
conditions with precise control over initial surface and inlet blood conditions. Each
of the subsequent chapters builds upon the complexity and strengths of the previous section, while employing new and novel aspects to the work. By incrementally
increasing the complexity and realism of the model system, it is possible to both
master the physical fabrication and experimental use of the devices and develop better understanding of successful design aspects and crucial biological implications of
using ex vivo model systems.

1.3

Problem Statement

The problems addressed in this work include the design, fabrication, characterization,
and use of a microfluidic based focal injury model for asking and answering novel
questions in thrombosis and hemostasis. One goal includes the development of a
system that is amenable to use with small volumes of blood that is mandated by the
non-sacrificial techniques of blood obtained from immensely important genetically
modified mice lines. Additionally, the ability to measure multiple outputs from a
single source blood sample simultaneously provides controls which are paramount in
highly variable hemostasis measurements, while serving as preliminary units which
could be used as future diagnostic devices. Finally, increasing the complexity of
the surface composition and the flow geometry will begin to recreate some of the
important complexities of in vivo thrombosis and hemostasis.
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Chapter 2
Microfluidic Model System
2.1

Abstract

Flow chambers allow the ex vivo study of platelet response to defined surfaces at
controlled wall shear stresses. However, most assays require 1 to 10 mL of blood
and are poorly suited for murine whole blood experiments. The objective of this
Chapter is to describe a system used to measure murine platelet deposition and
stability in response to focal zones of prothrombotic stimuli using 100 µL of whole
blood and controlled flow exposure. Microfluidic methods were used for patterning
acid-soluble collagen in 100 µm x 100 µm patches and creating flow channels with
a dead volume of 150 nL. Within 1 min of blood draw into PPACK and fluorescent
anti-mouse CD41 mAb, whole blood from normal mice or from mice deficient in the
integrin α2 subunit was perfused for 5 min over the patterned collagen. Platelet
accumulation was imaged at venous and arterial wall shear rates. After 5 min,
thrombus stability was measured with a “shear step-up” to 8,000 sec−1 . Wild-type
murine platelets adhered and aggregated on collagen in a biphasic shear dependent
manner with increased deposition from 100 to 400 sec−1 , but decreased deposition
at 1,000 sec−1 . Adhesion to patterned collagen was severely diminished for platelets
lacking functional α2 β1 integrin. Those integrin α2 -deficient platelets that did adhere
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were removed from the surface when challenged to shear step-up. PAR4 agonist
(AYPGKF) treatment of thrombus at 5 min enhanced aggregate stability during
shear step-up. This PAR4 signaling enhances aggregate stability by mechanisms
independent of other thrombin-dependent pathways such as fibrin formation.

2.2

Background

As anuclear cells, platelets are incompatible with in vitro genetic manipulation by
transfection or transduction. Consequently, genetically modified mice are a critical
tool for researchers studying the roles of platelet receptors and signaling in clot
initiation, propagation and stability [92]. Chemical [59], photoactivated [64], and
laser-induced [87] injury to vessels within genetically modified mice in combination
with intravital microscopy [26] are powerful tools for capturing the complex interplay
among platelets, endothelial cells and the subendothelial extracellular matrix. Yet,
it is difficult to control or quantify the biochemistry of the wall injury within these
models. In addition, local hemodynamic parameters such as wall shear stress are
uncontrolled and can vary in vessel injury models.
Useful complements to in vivo models are ex vivo flow champers that allow for
manipulation of shear stresses [8, 93, 104], controlled presentation of platelet stimuli
[95, 94], and evaluation of pharmacological agents [54]. Flow chambers for studying
platelet rolling, adhesion and aggregation over immobilized ligands have been critical
in understanding shear-dependent receptor-ligand dynamics [88, 6, 35]. However,
most parallel-plate and annular flow chambers require milliliters of fluid to perform
experiments over a relevant time scale. This volume of blood is easily obtained from
human subjects, but requires pooling or dilution of murine whole blood owing to the
relatively low total blood volume of a single animal (∼1 mL) [56, 96]. The cost of
pooling and the sacrifice of difficult to breed animals can be prohibitive when using
genetically modified mice to obtain data for a single experimental condition in a
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parallel plate flow chamber. Thus, current flow chamber designs are poorly suited
for research with murine blood.
We developed a method for characterizing murine platelet function under flow
using microfluidic and protein patterning techniques. This method addresses an
important need for researchers who want to perform ex vivo flow assays using small
volumes of blood from genetically modified mice. Owing to the small size of the
channels, the small volume (∼100 µL) of blood obtained from a retro-orbital plexus
was sufficient to perform an experiment, thus avoiding the need to sacrifice animals.
We validated the method by measuring platelet adhesion to patterned collagen at
venous and arterial wall shear rates and comparing platelet adhesion of wild-type
mice and mice deficient in collagen receptors. The stability of platelet-collagen and
platelet-platelet bonds were characterized by a high shear challenge. In addition,
the role of PAR4 activation on aggregate stability was measuring in a setting that
was independent of fibrin formation.

2.3

Materials and Methods Used

2.3.1

Fabrication of microfluidic devices

Microfluidic channels were fabricated in poly(dimethylsiloxane) (PDMS) using standard soft lithography techniques [22]. Photomasks were designed in LayoutEditor
(Jürgen Thies) and exported as ‘.dxf’ files. The dxf files were printed on highresolution transparencies at 10,000 dpi (OutputCity, Bandon, OR). Prior to photoresist spin coating, four inch <1 0 0> silicon wafers (Virginia Seminconductor,
Fredericksburg, VA) were cleaned with acetone and isopropanol then dehydrated
on a 200°C hotplate for 10 min. KMPR 1050 (MicroChem, Newton, MA) negative
photoresist was spun (CEE 100, Brewer Science Inc., Rolla, MO) to 500 rpm (100
rpm/sec) for 5 sec and then ramped up (300 rpm/sec) to 2,000-3,000 rpm for 30-45
sec to yield a film thickness of 50-80 µm. Following spin casting, the wafers were
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placed on a hotplate for 15 min at 100°C to drive the remaining solvent out of the
photoresist. The transparency photomask was taped to a glass substrate (5 in x 5
in) and brought into contact with the wafer using a Karl Suss MA4 contact aligner
(Karl Suss, Garching, Germany). The photoresist was exposed with a broadband
UV source that was filtered to eliminate wavelengths below 365 nm. The intensity of
the UV light was between 4.7 and 5.0 mW/cm2 and the exposure time of 3.25 to 4.25
min was used to achieve the manufacturer’s exposure energies (975-1,200 mJ/cm2 ).
Following exposure, the wafer was placed on a hot plate for 3 min at 100°C to crosslink the photoresist. After cooling to room temperature, the unexposed resist was
developed away in AZ300MIF (2.38% tetramethyl ammonium hydroxide and 0.261
N metal-ion-free developer, Clariant Corp., Somerville, NJ) for 7 min. Developed
wafers were triple-rinsed in DI water, nitrogen dried, and dehydrated at 80°C for at
least 10 hours prior to initial use in order to drive off any remaining water. Feature
heights were measured using a Tencor Alpha Step (KLA-Tencor Corp., San Jose,
CA).

2.3.2

Casting and preparation

Prior to casting, silicon masters were taped to 6 in polystyrene tissue culture dishes
(Fisher Scientific, Pittsburg, PA) and incubated with 1,1,2,2-tetrahydrooctyl -1trichlorosilane (United Chemical Technologies, Bristol, PA) under vacuum for 3 hr
to achieve a hydrophobic surface. Meanwhile, PDMS pre-polymer and curing agent
(Sylgard 184, Dow Corning, Midland, MI) were mixed at a ratio of 10:1 and degassed
under vacuum. The mixture was poured over the silane-treated master wafers and
allowed to set at 65°C for at least 3 hr in a gravity convection oven. After cooling, the molded devices were pealed from the master and cut to size using a #11
Xacto®blade. Fluidic and vacuum ports were punched with 0.75 and 1.2 mm Harris Uni-Core punches (Ted Pella, Redding, CA) respectively. Prior to use, PDMS
devices were cleaned in 1 N hydrochloric acid for 10 min, followed by immersion in
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an ultrasonic cleaning bath in acetone then ethanol for 10 min each. All surfaces
that were contacted with blood were blocked by incubation with 0.5% bovine serum
albumin (BSA, Sigma-Aldrich, St. Louis, MO) in HEPES buffered saline (HBS,
20 mM 4-(2-hydroxyethyl) -1-piperazineethanesulfonic acid, 150 mM NaCl, pH 7.4)
for 1 hr. Fluidic connections were made using blunt 21 gauge needles inserted into
Tygon tubing (0.020 in ID, 0.060 in OD, Small Parts Inc., Miramar, FL). Vacuum
was applied (∼10 psig) for reversible bonding using a direct connection between the
device and tubing which was connected to a variable pressure vacuum pump (Gast
Manufacturing Inc., Benton Harbor, MI).

2.3.3

Collagen patterning

Glass slides (75 x 28 x 1 mm, Fisherbrand, Fisher Scientific, Pittsburg, PA) were
cleaned in 1:1 (v:v) methanol : 17.1 N HCl for 30 min, followed by a 5 min rinse
in DI water, then dried in an 80°C oven for 30 min. Immediately before patterning,
slides were covered with Sigmacote (Sigma-Aldrich, St. Louis, MO), rinsed with DI
water, and dried with pressurized air in order to form a hydrophobic surface to aid in
protein adsorption. Patterning devices were aligned on the slide and held in place by
vacuum. A solution of 100 µL bovine or human solubilized type I collagen (PurCol or
VitroCol respectively, Advanced BioMatrix, San Diego, CA), 890 µL HBS, and 10 µL
0.1 N sodium hydroxide (with an optional 2 µL of 1 mM FITC to aid in interaction
localization) was mixed and immediately filled through the patterning device. The
collagen was allowed to polymerize at room temperature for 90 to 150 min. After
the desired incubation, the excess collagen solution was removed and the patterning
device removed. The second device to be used for blood perfusion was immediately
aligned on the slide in a perpendicular manner to the patterned collagen strip. The
flow channels were then immediately filled with a 0.5% BSA solution. This solution
prevented non-specific interactions of blood components with both the unreacted
glass surface and the PDMS device. As is shown in Figure 2.1, the total system
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Figure 2.1: Cartoon of patterning procedure with the patterning device (A) and the
flow device (B).
consists of two PDMS devices and one slide. By developing the system as a modular
pair of independent devices, it is possible to establish a general procedure to be
used regardless of the geometry of the flow channels or composition of the solutions
used to pattern. Utilizing reversible vacuum bonding techniques has provided this
capability: maintaining firm contact between the patterning device and the substrate
during the micropatterning procedure, while subsequently being able to remove that
device to place the flow device on the same substrate.

2.3.4

Mice

Flow assays were performed with whole blood from wild-type mice and mice deficient
in one or both of the primary collagen receptors. Knockout mice deficient in the
integrin α2 subunit were generated as previously described [15]. A double knockout
was created by crossing Fc receptor gamma chain (FcRγ)-deficient mice (Taconic
Farms, Hudson, NY) with α2 -deficient mice [96]. Mixed background litter-mate
animals were used as controls. All mouse studies were approved by the Institutional
Animal Care and Use Committee (IACUC) of the University of Pennsylvania.

2.3.5

Blood collection and platelet labeling

Prior to blood draw, rat anti-mouse CD41 (GPIIb, αIIb ) monoclonal antibody (clone
MWReg30, BD Biosciences, San Jose, CA) was conjugated to AlexaFluor®488 using
the AlexaFluor®488 Monoclonal Antibody Labeling Kit (Invitrogen, Carlsbad, CA)
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according to manufacturer’s instructions. Whole mouse blood, obtained by intraorbital eye bleed, was anti-coagulated with 93 µM (final concentration) Phe-ProArg-chloromethylketone (PPACK, Haematologic Technologies Inc., Essex Junction,
VT) and labeled with 1:100 (v:v) AlexaFluor®488-conjugated monoclonal antibody.

2.3.6

Whole blood flow assay

Channels were initially filled with 0.5% BSA in HBS to ensure that no bubbles
were trapped in the channel. Then, a volume of 100 µL of whole blood was placed
on the inlet of the device and withdrawn by a syringe pump (Harvard Apparatus
PHD2000, Holliston, MA) for 5 min at flow rates of 0.64, 2.5, and 6.4 µL/min to
achieve a full channel width-averaged wall shear rate of γ chan = 100, 400, and 1,000
sec−1 respectively. After 5 min of platelet accumulation on the collagen patch, the
shear rate was stepped-up to an average wall shear rate of γ chan = 8,000 sec−1 (50
µL/min) for 1 min to probe the stability of the aggregates.
Wall shear rate as a function of flow rate and position was calculated using an
analytical solution to the velocity profile in a rectangular duct [111]:
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where u(y, z) is the axial velocity at lateral location
 y and vertical positionz in a
w
−w
≤ y ≤ , 0 ≤ z ≤ h for a
channel of cross-sectional width w and height h
2
2
given volumetric flow rate Q. This equation obeys the no-slip boundary condition at
both the bottom and side walls while maintaining the null momentum flux boundary
condition across the centerline in both the x-y and x-z planes.
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2.3.7

Image capture and anaylsis

The adhesion, aggregation, and fragmentation of platelets were monitored continuously by epifluorescence microscopy. Images were captured using a CCD camera
(ORCA-ER, Hamamatsu, Bridgewater, NJ) mounted on an inverted microscope
(Olympous IX81, Center Valley, PA) with a 100 W mercury lamp (470 nm Ex /
525 nm Em). Images were captured continuously at 2 frames/sec (500 ms integration) using Slidebook software (Intelligent Imaging Innovations, Denver, CO). The
use of fluorescently labeled antibody allowed for continuous illumination of the field
of view without additional adhesion as has been reported using dye-loaded platelets
[40]. The central 60 µm of the collagen patch (750 × 372 pixels) and a region upstream (50 × 372 pixels) of the collagen were defined using a custom MATLAB script
(Mathworks Inc., Natick, MA). The average background of the upstream region was
calculated for each column and those values were subtracted from the reaction zone
pixel value to correct for background gradients across the width of the channel. The
background subtracted fluorescence intensity values were integrated over the collagen patch for each time point. Surface coverage was calculated by dividing the area
of pixels with a value greater than zero by the area of the collagen patch.

2.3.8

Introduction of platelet agonists to formed platelet aggregates

For stability studies involving PAR activation, platelet aggregates were built up from
PPACK-treated whole blood on patterned collagen for 5 min at 400 sec−1 . After the
deposition phase, the blood in the inlet was replace with HBS. After 30 sec of flow
at the same average wall shear rate (400 sec−1 ), the buffer was then removed and
replaced with 1 mM PAR4 agonist peptide (AYPGKF, Bachem, Torrance, CA).
Following 30 seconds of agonist presentation at 400 sec−1 , the HBS flow rate was
increased to an average wall shear rate of 8,000 sec−1 to allow measurements of
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Table 2.1: Summary of shear settings for murine blood characterization
Animal
WT (C57BL/6)
WT (C57BL/6)
WT (C57BL/6)
WT (BalbC/ByJ)
−/−
α2
−/−
α2 /F cRγ −/−

γ chan [sec−1 ]
100
400
1,000
400
400
400

γ central [sec−1 ]
n
126 (102-137)
7
492 (399-537)
6
1,260 (1,021-1,374) 6
492 (399-537)
8
492 (399-537)
7
492 (399-537)
6

thrombus stability.

2.3.9

Statistical analysis

Each data point represented a single blood draw from one animal. All data are
presented as mean ± standard deviation. The Mann-Whiteney U-test was used to
compare wild type blood perfused at 400 sec−1 (control) to each experimental group.
Groups with p-values less than 0.01 were considered significantly different from the
control. All calculations were performed using the Statistics Toolbox in MATLAB
(Mathworks, Natick, MA).

2.4
2.4.1

Results
Platelet accumulation in microfluidic channels

In developing an in vitro analog of a focal vascular injury (albeit without thrombin
production), we perfused whole blood over a discrete region of immobilized collagen. A collagen thin film (width of 100 µm) with fiber diameters of ∼15 nm was
patterned within a microfluidic channel along the length of a glass slide. Thirteen
individual channels with a cross-sectional area of 80 µm (height) × 100 µm (width)
were oriented perpendicular to the collagen strip and vacuum-sealed to the slide. A
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Figure 2.2: Shear profile across the bottom surface of the microfluidic channel.
summary of the experimental specifics (wall shear rates, genetic background, and
sample size) are shown in Table 2.1.
Due to the low aspect ratio (the ratio of the cross-sectional width to the crosssectional height, in this case 100 µm / 80 µm or 1.25) of the channels, the shear rate
variation was significant along the bottom channel wall. For example, at a flow rate
of 2.5 µL/min (whole channel width-averaged wall shear rate, γ chan = 400 sec−1 ),
the shear rate had a parabolic profile on the bottom channel where it was zero in
the corners and reached a maximum of 537 sec−1 in the middle as shown in Figure
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Figure 2.3: The shear profile (A) dictated platelet accumulation as measured by
fluorescence intensity (FI) in the channels with average wall shear rates γ chan = 100
(B), 400 (C), and 1,000 (D) sec−1 . The width of the channel was broken into 12
bins(10 × 100 µm) and the fluoresecence intensity represents the average of each bin
at each time point.

2.2. The implications of these non-uniform shear profiles are observed throughout
the representative micrographs throughout this chapter of work. However, it is
important to note that while the flow conditions at the collagen surface do not
directly mimic those found in the vasculature due to the rounded nature of blood
vessels, the experimental model system remains valid due to the transport of the
system, with a Péclet number <1, indicating that lateral diffusion is slow relative to
convection downstream and away from the reactive zone.
To account for the non-ideal flow profile due to wall effects of a low aspect ratio
channel, only platelet accumulation within the middle 60 µm of the channel (γ central )
were used for analysis throughout this Chapter. Within this middle section of the
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Figure 2.4: Images were taken at the specified time points from characteristic experiments. The direction of flow is from bottom to top.

channel, the range of wall shear rates were small compared with the entire width as
shown in Table 2.1, i.e. the wall shear rate was considered to be constant across this
section of the surface. The non-constant shear profile at the wall was reflected by
the heterogeneous platelet distribution at average wall shear rates of 400 and 1,000
sec−1 as shown in Figure 2.3. Platelet accumulation was highest at low shear rates
in the corners and less at positions in the middle of the channel at the highest shear
rates, while the lowest shear rate did not exhibit the same preference towards the
edge. This result, while not intended during experimental design, is one of note. The
distribution of platelet adhesion at various wall shear rate regions across the bottom
of the channel reflect a competition of phenomena which will be investigated later
in this Chapter.
Platelet adhesion was not observed upstream or downstream from the collagen
strip at any shear rate as shown in Figure 2.4. The localized platelet accumulation
is among the most important aspects of this work that distinguishes it from other
experimental systems used to analyze platelet accumulation under whole blood flow.
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The most frequently used device, a parallel plate flow chamber mounted on top of a
substrate that is uniformly coated with a protein of interest. The focal nature of this
system lends itself to investigation of processes confined in space to a relevant yet
small injury, i.e. the loss of several endothelial cells from the luminal blood vessel
surface. This technique is more sensitive to alterations in both initial adhesion and
secondary platelet recruitment to the reactive surface. Significantly shortening the
length for potential adhesion, activation, and propagation, bears a more stringent,
and possibly more relevant, model system.
For wild-type mouse blood, there was a rapid rise in platelet accumulation for the
first 3 min followed by minimal platelet deposition in the fourth and fifth minutes
as shown in Figure 2.5A. The dynamics of the platelet deposition curve were similar
to those reported in the laser-induced vascular injury model [26]. We observed a
delay of ∼20 sec followed by rapid platelet accumulation for 3 to 4 min. The time
to saturation in the laser injury model was 50% faster than in this model system,
which is likely to be a result of thrombin generation in the in vivo system, which was
absent in these experiments due to the high concentration of PPACK. By inhibiting
thrombin, we limit the thrombus growth to secondary platelet activators such as
ADP and TxA2 once the collagen surface has been covered with platelets. This is in
contrast to a system where thrombin is allowed to be formed and signal, recruiting
even more platelets and forming fibrin that serves as both a stabilizing network and
additional adhesive surface for continued platelet recruitment and activation.

2.4.2

Shear sensitivity of platelet deposition to patterned
collagen

In the absence of pre-adsorbed von Willebrand Factor (vWF), we observed a biphasic
response of platelet accumulation on patterned collagen. After a 5 min perfusion over
collagen, there was a significantly (P <0.01) less platelet accumulation and surface
coverage in the central zone (γ central ) at 126 sec−1 and 1,260 sec−1 compared with
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Figure 2.5: A. Kinetic traces of platelet accumulation for wild-type mouse blood
at three shear rates. B. Endpoint fluorescence and surface area measurements of
formed aggregates.
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492 sec−1 (Figure 2.5B). At an average wall shear rate of 126 sec−1 , platelet adhesion
was uniform across the width of the channel, but there were fewer platelet aggregates
compared with 492 sec−1 . At an average wall shear rate of 1,260 sec−1 , there was
little platelet accumulation in the center of the channel. The few platelet aggregates
that were observed may be due to adsorption of vWF from from the plasma onto
the collagen. While adsorption of vWF onto collagen from flowing mouse blood is
expected during the experiment, platelet deposition will continually cover the collagen available for adsorption during the 300 sec perfusion. The observed biphasic
response illustrated in Figure 2.5 was most likely a result of competing effects where
increasing flow increases the platelet flux to the collagen surface but also increases
the force loading on adhesive bonds, reduces interaction times, and dilutes reactive
species, resulting in less efficient platelet adhesion at higher flow rates. This competition highlights an interesting and dynamic characteristic of platelet accumulation,
and perhaps may inform some of the regulation that occurs to limit thrombus size
in vivo. Among the key characteristics of any successful hemostatic system is the
ability to prevent excessive clot formation that leads in either vessel occlusion or
mechanically unstable clot formation, leading to dangerous and potentially deadly
emboli. Save for the alterations in vascular smooth muscle tension and other systemic mediators of vascular tone, as thrombi continue to form into the blood vessel
lumen, the shear rate continues to increase, assuming volumetric flow rates are maintained. This result may indicate that, among other transport considerations such
as the removal of active species from the site of injury, the decreased interaction
times and increased force load on bonds limits the amount of thrombus growth that
prevents pathological clotting scenarios during healthy hemostasis.
For γ central = 126 sec−1 , extending the perfusion time to 20 min did not result in
increased platelet accumulation as shown in Figure 2.6. For these longer experiments,
we observed continuous addition and removal of platelets from the aggregate surface,
but there was no net change in the integrated fluorescence intensity after the first 300
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Figure 2.6: Kinetic traces of platelet accumulation for wild-type mouse blood for 5
and 20 min time courses (n = 6).
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sec. These data suggest that the initial platelet layer on collagen dictates the final
extent of thrombus growth in the absence of thrombin. Again, this is most likely
the case for this model system without the generation of thrombin for subsequent
platelet signaling and fibrin generation.

2.4.3

Accumulation of platelets with collagen receptor deficiencies

We performed flow experiments over patterned collagen with whole blood from mice
deficient in one or both of the primary collagen receptors. Single knockout mice
were deficient in the α2 integrin subunit. A double knockout deficient in both FcRγ
and α2 was used as a negative control. The knockout mice have a mixed genetic
background consisting of C57BL/6J, BalbC/ByJ and 129Sv/ImJ mice strains. Both
C57BL/6J and BalbC/ByJ were used as wild type controls.
There was no statistical difference (P = 0.75) between platelet accumulation and
aggregate fragmentation between the two wild-type controls as shown in Figure 2.7.
While seemingly mundane, this is not an insignificant result. Inbred mice have long
been the workhorse of hemostasis researchers in need of studying mutated proteins.
However, the wide variety of wild-type mouse strains used during the genetic manipulation processes have exceedingly wide, upwards of an order of magnitude in
circulating vWF levels [101]. This discrepancy arises from many known and unknown sources, from differences at the transcriptional, translational, execratory, and
degradation aspects of soluble vWF homeostasis. The measurements confirming the
lack of statistically significant difference between the two wild types provides solid
background for the investigation of the genetic mutants.
Platelets deficient in the α2 integrin subunit had a diminished ability to adhere
to patterned acid soluble collagen at an average wall shear rate of 400 sec−1 as
shown in Figure 2.8. There was a significant difference (P = 0.0012) in platelet
accumulation for mice deficient in the α2 integrin compared with wild-type mice.
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Figure 2.7: Kinetic traces of platelet accumulation for two wild-type control mouse
strains (n = 6).
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Figure 2.8: Kinetic traces of platelet accumulation for wild-type and two collagen
receptor knockout mouse strains (n = 6).
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The small number of platelets that did adhere was presumably initiated through
the GPIb-IX-V complex on platelets and vWF from the plasma adsorbed to the
collagen. These data show that the α2 β1 receptor was necessary for firm adhesion to
acid-soluble collagen under flow. This data is in agreement with published results
and will be discussed in further detail later in this Chapter.

2.4.4

Thrombus stability and PAR signaling

A useful feature of flow chambers is the ability to control the shear rate and make
changes to it during the course of a single experiment. Microfluidic chambers, due to
their small dead volumes, allow extremely high shear rates to be tested for extended
periods of time even with very small reagent volumes. In each flow experiment,
we monitored platelet accumulation for 5 min at a constant wall shear rate then
increased the average wall shear rate to γ chan = 8,000 sec−1 for 1 min. Thrombus
stability for this was defined by the percentage decrease in integrated fluorescence
intensity and loss in surface coverage following the step up in shear rate. During the
1 min exposure of the pre-formed thrombus to ultra high shear rates of 8,000 sec−1
(a level known to cause shear-induced platelet activation (SIPA) in cone-and-plate
viscometers [100]), we found no indication that SIPA enhanced thrombus buildup
during the 1 min exposure. As seen in Figures 2.5A and 2.8, total fluorescence
intensity decreases by 15-25% for platelet aggregates formed at both venous and
arterial shear rates. Platelets deficient in the α2 subunit had a severe adhesion
deficiency, covering less than 5% of the surface after the 5 min accumulation phase.
Upon shear rate increase to 8,000 sec−1 , we observed a complete removal of platelets
from the surface as shown in Figure 2.8, demonstrating strict requirement for α2 β1
in stable adhesion for murine platelets to acid soluble type I collagen.
Thrombin is critical in clot formation and stability by distinct pathways involving platelet activation via protease activated receptor (PAR) signaling, enhanced
recruitment of additional platelets, and fibrin generation. In order to investigate
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Figure 2.9: Changes in fluorescence intensity and surface coverage after thrombus
exposure to HBS or PAR4 peptide (n = 6).

mouse PAR4 signaling in the absence of active thrombin (which was blocked by 93
µM PPACK throughout the entirety of the experiment) and fibrin formation, we
introduced an activating peptide after the platelet thrombi were formed to induced
platelet signaling via the G-protein coupled receptor. In addition to the signaling
pathways activated by the collagen receptor GPVI and the feedback receptors of released secondary messengers (ADP and TxA2 ), PAR4 activation leads to substantial
phospholipase C β activation, resulting in large surges in intracellular calcium and
subsequent integrin activation and granule release. By selectively infusing murine
PAR4 activating peptide (AYPGKF) over pre-formed platelet aggregates, it was
possible to determine the effect of PAR4 signaling on both platelet-platelet and
platelet-collagen bond strength when subjected to a high shear challenge.
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PAR4 activation of platelets following accumulation on collagen led to a stabilization of the thrombus compared with a buffer control as shown in Figure 2.9. There
was a significant difference for both the percentage of total fluorescence intensity
and area loss (P = 0.002) between the buffer control and the experimental group.
While the initial size of each thrombus mass at 300 sec may vary due from experiment to experiment due to intrinsic intra-mouse variability (as indicated in 2.5),
we found that every aggregate lost mass at 8,000 sec−1 , and that the percentage
decrease in mass was highly consistent. Because each and every thrombus formed,
regardless of variations in its initial size after 300 sec of formation time, displayed
a decrease in fluorescence when exposed to 8,000 sec−1 , the percentage decrease in
total fluorescence was measured to be 20 ± 3 % (n = 6).

In Figure 2.9, we report a 55% reduction in percentage thrombus volume loss with
PAR4 agonist because an untreated thrombus has an approximately 20% decrease
in fluorescence intensity after exposure to 8,000 sec−1 , while a thrombus treated
with PAR4 agonist only has a 10% decrease in fluorescence intensity. This decrease
is statistically significant (21.3 ± 2.1% loss with buffer vs. 9.5 ± 4.7% loss with
PAR4 agonist, P = 0.002, n = 6). In terms of percent loss in surface coverage, we
report in 2.9 a 90% reduction in percent surface loss with PAR4 agonist (18.9 ±
6.9% area loss with HBS vs. 1.9 ± 2.6 % loss with PAR4 agonist; P = 0.002, n
= 6). Thus, regardless of the initial mass of the thrombus at 300 sec (which can
vary somewhat between mice as shown in the error bars in Figure 2.5), each of these
thrombi will lose about 20% of its volume when exposed to 8,000 sec−1 and this loss is
substantially mitigated by 50% when the aggregates are exposed to a PAR4 agonist.
While the total volume loss is only 20% with a shear step-up to 8,000 sec−1 under
these experimental conditions, the clinical significance of embolism of 20% of total
clot volume is substantial and results shown in Figure 2.9 provide a quantitative in
vitro method to interrogate thrombus stability. The increase in stability of mouse
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Figure 2.10: Changes in fluorescence intensity and surface coverage after human
platelet thrombus exposure to HBS or PAR1 peptide (n = 6).
platelet aggregates was likely due to PAR4-mediated enhancement of both α2 β1 dependence platelet adhesion on collagen and αIIb β3 -dependence platelet-platelet
interactions.
Similar results were obtained in analogous experiments performed with human
platelet thrombi activated with the PAR1 agonist, SFLLRN, where 670 µM SFLLRN
reduced percentage FI loss from 40% to 15% (P = 0.001, n = 8) compared with HBS
control as shown in Figure 2.10.

2.5

Discussion

Microfluidic techniques are ideally suited for ex vivo phenotyping of blood, especially
when minimal volumes are available, such as from genetically modified animals or
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in point-of-care diagnostic situations. The shear stress is a user-defined parameter
in this microfluidic model system that can be modulated during the course of an
experiment. This feature allowed us to build up platelet aggregates at one shear rate
and then probe the stability of platelet-ligand and platelet-platelet bonds at higher
shear rates. We detected disaggregation of wild-type mouse platelets during a shearup challenge of 8,000 sec−1 . There was evidence of platelet-platelet and plateletcollagen bond failure, indicating instabilities at this pathological wall shear rate.
Platelet deposition was shear dependent and biphasic 2.5, revealing the competition
of enhanced platelet delivery to the wall, reduced interaction times, and increased
forces as flow increases. In α2 -deficient mice, those platelets that did adhere were
almost completely removed after shear-up challenge, suggesting that stable adhesion
to immobilized collagen was α2 β1 dependent. PAR4 activation led to increased
stabilization to resist shear forces, suggesting a role for thrombin signaling in clot
stability independent of platelet recruitment or fibrin generation.
By manipulating the thrombin-driven platelet signaling independently of fibrin
formation due to thrombin activity, it was possible to begin dissecting the implications of PAR signaling on aggregate stability. PAR4 signaling significantly improved
the ability of focal collagen-initialized platelet thrombi to remain adherent in under a pathological shear rate of 8,000 sec−1 . Measurements of loss of area coverage
and total fluorescence intensity probed the stability of platelet-collagen (α2 β1) and
platelet-platelet (αIIb β3) bond strengths following PAR4 signaling, respectively. We
observed that PAR4 signaling increased the stability of the initially bound platelets
to collagen (i.e. reduced the percentage surface coverage loss) as well as increased
platelet-platelet stability, most likely via αIIb β3 -fibrinogen complexes.
In this report, we have scaled down the conventional flow chamber assay to a
microfluidic platform. The salient advantage of this adaptation is the small volumes
sufficient to run a complete flow experiment under physiologically relevant flow conditions for hemostastically relevant times. Other reports of murine blood in ex vivo
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flow assays using either pooled [56] or diluted [96, 75] whole blood and often require
the sacrifice of several animals. Dilution reduces plasma protein concentrations and
alters the effect of red blood cells on platelet drift toward the wall, which is crucial
in focal injury models such as this one. With a microfluidic system, no dilution
or pooling was necessary to run a flow experiment over a relevant time frame for
thrombosis via a non-lethal blood collection method. An important parameter for
any ex vivo function test of platelets is the time between blood collection and the
start of the experiment, as changes effect the blood’s characteristics due to lack of
active mediators excreted by endothelium, such as nitric oxide and cyclic AMP. A
system requiring more than 100 µL of blood would mandate a cardiac puncture and
possibly the pooling of multiple animals’ blood. These procedures can take 10 min
to 1 hr depending on the number of animals and require the addition of additional
factors to ensure that platelets remain quiescent. In our system, the time from blood
draw to first platelet deposition in the image field was typically less than 1 min, a
significant advantage in point-of-care diagnostic situations.
Microfluidic channels in combination with protein patterning more closely represents the focal nature of in vivo vascular injury models than conventional flow chambers that utilize uniformly coated surfaces across hemostatically irrelevant length
scales (on the order of mm for most typical hemostasis injuries). While parallel
plate chambers are amenable to surface patterning proteins [70, 80, 79], they have
higher volume requirements than microfluidic channels. In addition, blood flow in
microfluidic channels can more accurately mimics the hemodynamics found in arterioles and venuoles [103, 44]. Annual flow chambers such as glass capillary tubes have
low volume requirements, but are less amenable to discrete surface patterning with
collagen and other molecules of interest in the absence of sophisticated and complex patterning techniques [91]. In configurations where proteins are adsorbed to
the entire surface, there can be marked boundary layer depletion of platelets where
adhesion decreases with axial position [94]. Due to the short length of the collagen
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patch in the direction of flow, platelet deposition was essentially uniform from the
front of the patch to the back of the patch, especially within the central 60 µm
region. Microfluidic techniques can be applied to explore several experimental conditions within a single device. For examples, current reports [38] have developed a
device to study platelet adhesion over a range of shear stresses (0.5 to 50 dynes/cm2 ),
although without the focal patterning utilized in this system, with <100 µL of whole
blood.
Our patterning of acid soluble type I collagen yielded a homogeneous and repeatable thin film. Previous work [97] used blocking antibodies with human platelets
and found that adhesion to acid soluble type I collagen under flow was dominated
by α2 β1. Our observations that murine platelets deficient in the α2 subunit cannot
adhere to acid soluble collagen are consistent with these results. In contrast to soluble collagen, platelet arrest during flow over fibrillar collagen preferentially requires
GPVI for adhesion and activation and demonstrates only a supporting role for α2 β1
[75]. While we used platelet-collagen interactions as proof-of-principle in this report,
micropatterning techniques can be extended to other prothrombotic molecules such
as vWF [70, 80], fibrillar collagen and tissue factor [51, 79]. While fibrillar collagen is
more physiological and has been tested in this system, the active area in the device is
so small that the number of collagen fibers per test area was highly variable. This is
because deposition of fibrillar collagen was heterogeneous at the micron length scale.
Consequently, we chose to used a homogeneous, reproducible collagen thin film for
system characterization.

2.6

Conclusions

As thrombosis and hemostasis researchers continue to develop genetically modified
animals and injury models, ex vivo assays need to adapt and evolve to complement
features of the in vivo animal models. Flow-based assays are especially important
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because they mimic the shear stresses experienced by platelets in blood vessels. Here
we applied microfluidic methods that have several advantages over conventional flow
chambers including: (i) low volume requirements (<100 µL) that circumvent the
need to dilute or pool murine whole blood, (ii) spatially defined presentation of a
prothrombotic surface that mimics the focal nature of vascular injury with discrete
boundaries at the injury site, and (iii) ability to probe thrombus stability at high
shear stresses. These features allow a high number of replicates and may be useful for
testing the pharmacological activity of small molecules or biologics in the presence
of physiologically relevant flow.
This work served as a proof-of-principal that the combination of protein micropatterning with microfluidic blood perfusion can be used as a model system of
thrombosis. The use of simple, single inlet, single outlet, single channel devices
minimized the complexity of a new and unproven system. Some of the subtle flexibilities of investigating the role of thrombin receptor effects on thrombus stability
proved that a wide range of previously physically unrealizable experiments could be
performed utilizing the small material requirements and dead volumes of this microfluidic system. However, the method itself is limited in its throughput, though
not as much as its contemporaries, in that experimental conditions are run one at
a time. This limitation become prohibitive when working with human donors, who
unlike a group mice, are not amenable to a series of blood draws when the next
experiment is ready to commence. Rather, blood, especially platelet function, begins to significantly change when outside of the body for more than an hour, as can
be understood by changes in temperature, flow, and soluble mediators continuously
released by the endothelium in vivo.
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Chapter 3
Platelet Antagonist Dose
Responses
3.1

Abstract

Determination of patient-specific response to anti-platelet agents facilitates proper
dosing for both acute and chronic prophylaxis. “Closed” systems (with or without flow) may fail to predict pharmacological potency in situations where platelets
rapidly accumulate under flow conditions at a site of thrombosis (“Open” systems).
Using an 8-channel microfluidic flow assay of human whole blood with corn trypsin
inhibitor (± PPACK) perfused over focal zones of collagen, dose-response curves were
measured for pharmacological agents at a wall shear rate of 210 sec−1 . The P2Y1 inhibitor MRS 2179 (IC50 = 0.233 ± 0.132 µM) and P2Y12 inhibitor 2-MeSAMP (IC50
= 2.558 ± 0.799 µM) were potent blockers of secondary platelet accumulation under
flow, while the P2X1 inhibitor (NF 449) and apyrase failed to reduce platelet accumulation. MRS 2179 and 2-MeSAMP had undetectable effects on initial platelet
adhesion to collagen. Numerical simulation of convective-diffusive transport and
apyrase-mediated catalytic degradation of ADP indicated that ultra-high concentrations of apyrase (∼2000 U/mL) would be required to have the same effect under
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flow as much lower concentrations (1 U/mL) currently used in closed systems (aggregometry or cone-and-plate viscometer). This is the first evaluation of IC50 ’s for
P2Y12 and P2Y1 antagonists under controlled flow conditions. Evaluation of antiplatelet agents in open flow systems demonstrates that inhibition of either ADP by
apyrase or antagonism of P2X1 signaling had no effect on platelet accumulation. This
technique provides a platform for rapidly investigating effective of anti-thrombitic
therapies simultaneously in a model injury system.

3.2

Background

Anti-platelet therapies have been successful in preventing excessive clotting in patients with a wide range of pathologies [12, 10]. Targeting the thromboxane A2
pathway with aspirin [113] or ADP feedback via the P2-family of platelet receptors
[32, 41] reduces secondary platelet activation pathways [48] and reduce pathologically
excessive clot formation while not interfering with primary platelet adhesion and activation necessary for general hemostasis. However, bleeding risks and variability of
patient response to anti-platelet therapies often mandate careful monitoring of patients. For example, a significant number of patients fail to respond to anti-platelet
drugs, clopidogrel in particular [112].
The most popular current target of anti-platelet therapy is the G protein-coupled
receptor P2Y12 , which is one of the three P2-family proteins found on the platelet
surface [58]. The receptor is activated by the binding of its ligand, ADP, released
from activated platelets at the site of injury, which in turn causes activation of
Gi2 , inhibition of adenylyl cyclase, and activation of PI3 kinase, a rise of cytosolic calcium, and finally granule release and shape change [33]. P2Y1 is the second
G protein-coupled receptor that has been targeted as an anti-platelet therapeutic
target. Binding of ADP to this other receptor on the platelet surface, which is Gq
coupled [78], leads to phospholipase C β (PLCβ) activation and subsequent platelet
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activation. The third P2-family receptor, the P2X1 receptor, is an ATP ligand-gated
ion channel [81], which directly leads to the influx of calcium from the extracellular
milieu. The role of platelet P2X1 signaling is less well defined with respect to platelet
activation and thrombus formation than the P2Y receptors [77]. Finally, the enzyme
apyrase (ATP-diphosphohydrolase E.C.3.6.1.5) which actively hydrolyzes both ADP
and ATP to the mono-phosphorolated and hemostatically irrelevant AMP is used
ubiquitously in aggregometry, cone-and-plate viscometry, and other in vitro experimental techniques to remove the ligands of the P2 family receptors from the bulk
solution. Endogenous ATP- and ADP-ases exist throughout the vasculature (CD39)
to keep circulating concentrations below activating levels. The therapeutic potential
for recombinant apyrase [106] and solubilized CD39 [24] is currently being explored
as a potential anti-platelet therapy.

Evaluation of platelet function and pharmacological agents can occur in closed
systems of constant volume that lack flow (eg. intracellular calcium measurement,
automated calibrated thrombography) or include flow (eg. aggregometry or coneand-plate viscometry). However, these laboratory approaches fail to recreate the
relevant transport characteristics in that intravascular thrombosis is an open system
where blood is continually flowing over a thrombotic site. Various in vitro flow systems allow precise control of hemodynamics, surface characteristics, and inlet blood
pharmacology [97, 20, 80, 72, 38] which have resulted in deeper understandings of the
complicated interplay between flow, initiation, and thrombus growth. In open systems, the rapid accumulation of platelets at a surface leads to platelet concentrations
greatly exceeding those found in whole blood, and the delivery/removal of species by
convection may impact the efficacy of pharmacological agents. If an agent is potent
in a closed system but lacks efficacy in an open system, then the therapeutic benefit
of the agent may be limited with respect to reducing intravascular thrombosis under
flow.
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3.3
3.3.1

Materials and Methods
Blood collection and labeling

Blood was obtained from healthy individuals who had refrained from taking medications for at least ten days prior to donation. Informed consent was obtained from
each volunteer, and phlebotomy was performed in accordance with IRB approval
from the University of Pennsylvania’s Office of Regulatory Affairs and the Declaration of Helsinki.
Whole blood was drawn via venipuncture into corn trypsin inhibitor (CTI, Haematologic Technologies Inc., Essex Junction, VT) to a final concentration of 50 µg/mL
to inhibit Factor XIIa. Although the physiological relevance and importance of FXII
is currently under investigation [109]. Aliquots of 200 µL whole blood were labeled
with 4 µL of AlexaFluor 647 conjugated anti-CD41 (αIIb ) antibody (Clone PM6/248,
AbD Serotec, Raleigh, NC), which had no effect on platelet function (results not
shown). In order to inhibit thrombin function in some experiments, H-D-Phe-ProArg-chloromethylketone (PPACK, Calbiochem, San Diego, CA) was added to a final
concentration of 100 µM. CTI-treated whole blood was perfused through the fluidic
chamber within 15 min of phlebotomy.

3.3.2

Microfluidic fabrication and protein patterning

Microfluidic devices were fabricated in poly(dimethylsiloxane) (PDMS, Sylgard 184,
Ellsworth Adhesives, Germantown, WI) using well established techniques [22]. Detailed fabrication methods and patterning techniques were performed similarly to
those detailed in Section 2.3.3. In order to ensure physical separation between the
eight blood samples located in relative close proximity on the chip during the experiment, a simple second PDMS layer was used as pseduowells. PDMS (10:1 v:v
base:curing agent) was mixed to a final volume of 99 mL and poured into a clean
150 mm petri dish. After allowing to cure at 80 °C for at least 4 hours, the solid
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cylinder was removed. A pattern was placed beneath it and the single cylinder was
cut into 20 individual well sections using an Xacto®knife that would fit on top of
the devices with the microchannels. Using one flow device as a guide, the location of the eight inlets were marked on the surface of the plain PDMS using a felt
marker. Large holes were then punched from the well-piece using a 4 mm diameter
punch (Ted Pella, Redding, CA). The flow device and wells were irreversibly bonded
by treating the two adjoining surfaces with a Tesla-coil-induced lab corona treater
(115 V, Electro-Technics Products Inc., Chicago, IL) for 30 seconds, bringing the
two sides immediately into contact, and curing overnight at 60°C under ∼2 lb of
force. Briefly, glass slides (75 mm × 50 mm × 1 mm, Fisherbrand, Fisher Scientific,
Pittsburg, PA) were cleaned with Methanol:HCl as described in Section 2.3.3, then
functionalized with Sigmacote (Sigma-Aldrich, St. Louis, MO) to form a hydrophobic surface to aid collagen adsorption. Human Type-I collagen (Vitrocol 3.0 mg/mL,
Advanced BioMatrix, San Diego, CA) was diluted to 300 µg/mL in HEPES buffered
saline (HBS, 20 mM N-(2-Hydroxyethyl)piperazine- N’-2-ethanesulfonic acid, 150
mM NaCl, pH 7.4) with 10 µL 0.1 M sodium hydroxide solution to neutralize pH to
7.0 to a final volume of 1 mL. Microfluidic devices were then filled with the solution
and allowed to incubate at room temperature for 150 min to polymerize the collagen into a thin film on the surface of the slide. Excess solution was then removed,
immediately followed by placement of the flow device aligned on the formed collagen
region. A solution of 0.5 % bovine serum albumin (BSA) in HBS was then filled
through the channels and allowed to sit at room temperature for at least 60 min in
order to prevent non-specific platelet binding to both the PDMS and the un-reacted
glass surface. The device used to perfuse the blood over the collagen strip is shown
in Figure 3.1.
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Figure 3.1: A. CAD schematic of eight channel device. B. Photograph of one device
used.

3.3.3

Flow cytometry and device characterization

Fluorescent particles (FITC and PE-Cy5 Easy Calibration Kits, Spherotech, Lake
Forest, IL) were diluted 1:9 (v:v) in 0.5 % BSA in HBS to a particle concentration
of approximately 2 x 105 particles/mL. Control mixtures of 10 µL of each type of
fluorescent particle (FITC Peaks 2, 3, 4, and 5 and PE-Cy5 Peaks 2, 3, 4, and 5)
were mixed in a microcentrifuge tube. Particles were assigned to input positions on
the flow device using a random number generator and perfused through the device
using a gastight syringe (250 µL Hamilton Company, Reno, NV) mounted on a
syringe pump (PHD 2000, Harvard Apparatus, Holliston, MA) at a volumetric flow
rate of 16 µL/min for 5 min. The effluent was collected in Tygon tubing (0.020 in
ID, 0.060 in OD, Fisher Scientific, Pittsburg, PA) and subsequently infused into a
microcentrifuge tube for assaying. Flow cytometry was performed on an Accuri A6
flow cytometer (Accuri Cytometers Inc., Ann Arbor, MI) fitted with the CSample
automated plate sampler. Gates were applied in CFlow Plus software and kept
constant across all samples analyzed.
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3.3.4

Inhibitor preparation

2’-Deoxy-N6 -methyl adenosine 3’,5’-diphosphate (MRS 2179), Grave VIII apyrase
from potato (Solanum tuberosum), 2-Methylthioadenosine 5’-monophosphate (2-MeSAMP) (Sigma Aldrich, St. Louis, MO), and 4,4’,4”,4”’-[Crabonylbis(imino-5,1,3benzenetriyl-bis(carbonylimino))]tetrakis-1,3-benzenedisulfonic acid (NF 449, Tocris
Bioscience, Ellsiville, MO) were dissolved in HBS to working concentrations. Dilutions of compounds were made to ten fold the desired final concentration in HBS on
the day of the experiment, after which the inhibitor was added at a ratio of 1:9 to
fluorescently labeled whole blood and allowed to incubate at 5 min at room temperature, with gentle mixing at 2 min, except for apyrase which was added immediately
prior to perfusion. Final inhibitor concentrations used were: MRS 2179 (0 - 10 µM),
2- MeSAMP (0 - 200 µM), NF 449 (0 - 10 µM) and apyrase (0 - 100 U/mL).

3.3.5

Platelet accumulation measurement

Blood samples incubated with the given inhibitors were introduced to the inlet of
the flow device and immediately perfused through the device at a controlled volumetric flow rate of 15 µL/min for an average wall shear rate at the collagen patch
of 210 sec−1 (for rectangular channels of cross sectional dimensions of 60 µm × 250
µm). Assembled devices were mounted on an inverted microscope (IX81, Olympus
America Inc., Center Valley, PA) and imaged using a CCD camera (ORCA-ER,
Hamamatsu, Bridgewater, NJ) illuminated with a mercury lamp (100W, 620 Ex /
700 nm Em). Fields of view were captured using a 2X objective, integrating for
1,000 ms every 5 sec for 5 min.

3.3.6

IC50 calculation

The far left and far right collagen regions were identified manually, with intermediate
and corresponding background regions interpolated using a custom MATLAB script
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(MathWorks, Natic, MA). Background-corrected fluorescence values were fit using a
four parameter logical model shown in Equation 3.1:

FI = A +

A−B
 D
1 + [I]
C

(3.1)

with [I] representing the inhibitor concentration, F I the background corrected
fluorescence of the corresponding region, A and B the minimum and maximum
intensities respectively, with C and D the fit parameters. The data were fit using a
least-squares non-linear curve fitting routine (MATLAB, Data Analysis Toolbox).

3.3.7

Computational model of apyrase activity in open and
closed systems

In order to investigate the effect of convective mass transport on the hydrolysis of
ADP and ATP by apyrase, a set of finite element method numerical simulations were
performed. A commercial software package (COMSOL Multiphysics, Burlington,
MA) was used to solve both the steady-state flow profile and the coupled convectiondiffusion-reaction system in a 2-dimensional domain approximating the 2 mm surrounding the 250 µm reactive zone with a height of 60 µm. The hydrolysis of ADP
by apyrase was approximated by classic Michaelis-Menten kinetics using the published KM for apyrase with ADP and ATP [17]. The influx of ADP at the reactive
surface was set to an experimentally determined rate corresponding to full platelet
activation [71], which is comparable to previously estimated values [37, 36], and a
value calculated from the platelet flux to a collagen surface at the given shear rate
[5] and the approximate ADP concentration per platelet [45]. Parameter values and
boundary conditions are shown in Table 3.1.
Grid independence was performed by evaluating the near-wall average concentration for a series of increasingly refined grids consisting of 13,840, 55,360, 105,429, and
221,440 triangular elements, each with less than 0.001 % error from the estimate of
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Table 3.1: Physical parameters and boundary conditions used in numerical simulations of ADP concentrations around at a growing thrombus surface. *: Calculated
from the Wilkie-Change correlation for molecular diffusivity [11]. **: Determined
by calculating the maximum velocity for a rectangular duct with cross-sectional dimensions of 150 µm × 60µm and a volumetric flow rate of 1.88 µL/min.

Parameter
Density of whole blood
Viscosity of whole blood
Diffusivity of ADP and ATP
Flux of ADP (JADP )
Flux of ATP (JAT P )
vx,max
KM,ADP
KM,AT P
kADP
kAT P

Value
1.06 x 10 kg/m3 (25 °C)
4.7 x 10−3 Pa-sec (25 °C)
1.14 x 10−10 m2 /sec
−6
4.4 x 10 and 7.8 x 10−10 mol/m2 -sec
2/3 x JADP
4.18x10−3 m/sec
0.25 mol/m3
0.06 mol/m3
100 µmol/min/mg
1,210 µmol/min/mg
3

Reference
[36]
[36]
*
[71, 53]
[45]
**
[17]
[17]
[17]
[17]

the zero grid spacing solution using Richardson extrapolation [86]. The intermediate
grid (105,429 elements) was used in order to optimize solution time and accuracy.
Steady-state momentum and mass balance calculations were performed using a direct
solver (UMFPACK) on a workstation (dual 2.2 GHz processors, 12 GB RAM).
KM,AT P

k

KM,ADP

k

AT P
AT P + apyrase ←−−−→ AT P · apyrase −−
−→ ADP + apyrase

ADP
ADP + apyrase ←−−−→ ADP · apyrase −−
−→ AM P + apyrase

(3.2)

(3.3)

Let BAT P = cAT P · apyrase and BADP = cADP · apyrase.
dcAT P
= −k1 BAT P
dt

(3.4)

dcADP
= k1 BAT P − k2 BADP
dt

(3.5)
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Tapyrase = BAT P + BADP + F ree

(3.6)

BAT P =

cAT P · F ree
KM 1

(3.7)

BADP =

cADP · F ree
KM 2

(3.8)

Combining Equations 3.6, 3.7, and 3.8


BAT P =

cAT P · Tapyrase 1 − KMc2ADP
+cADP
cAT P ·cADP
KM 1 + cAT P − KM 2 +cADP




BADP =

cADP · Tapyrase 
1−
KM 2 + cADP


(3.9)
 

cAT P 1 − KMc2ADP
+cADP
cAT P ·cADP
KM 1 + cAT P − KM 2 +cADP



(3.10)

The competition between ADP and ATP for hydrolysis by apyrase was modeled using
classical Michaelis-Menten kinetics operating under the fast equilibrium assumption,
shown by Equations 3.7, and 3.8.
The open simulations were simulated with the following settings: Subdomain
conditions:
∇ • (−DADP ∇cADP ) = kAT P BAT P − kADP BADP − vx (y) • ∇cADP
∇ • (−DAT P ∇cAT P ) = −kAT P BAT P − vx (y) • ∇cAT P

(3.11)
(3.12)

Boundary Conditions:
Inlet: cAT P = cADP = 0
Reactive surface:

dcAT P
dy

= JAT P ,

dcADP
dy

= JADP

Outlet: Jout,AT P = vx (y)cAT P (x = L, y), Jout,ADP = vx (y)cADP (x = L, y)
Walls and centerline: ∇cAT P = ∇cADP = 0.
The closed system used the same binding kinetics and reaction terms (Equations 3.4,
3.5, 3.9, 3.10 ) with different ADP release.
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ṁADP

3
= √ exp
τ 2π



−9(t − τ )2
2τ 2


· TADP , 0 < t ≤ 2τ
(3.13)

0, t > 2τ
Equation 3.13 describes a normal distribution for ADP release to a cumulative
total of TADP , with a time of maximal instantaneous release τ . The total ADP in the
system was estimated by the typical volume and platelet count in an aggregometry
cuvette (0.5 mL cuvette, 2×108 platelets/mL) with the same approximate ADP
concentration per platelet used in the low flux value for the open system [45], with the
maximal release time estimated from the maximal rate of ADP release [98, 18] at 30
sec, leading to a maximal ADP concentration of 6 µM in the absence of degradation.
By matching effective flux values between the open and closed systems, the best
attempt was made to create directly comparable numerical approximations of the
corresponding in vitro systems.

3.3.8

Statistical analysis

Data were compared to appropriate controls using the Mann-Whitney U-test with
p-values less than 0.01 considered statistically significant. All data are plotted as
the mean ±standard deviation. All calculations were performed using the MATLAB
Statistics Toolbox.

3.4
3.4.1

Results
Device characterization

To verify equal flow rates in each of the eight channels, each inlet reservoir was
spiked with a unique bead tracer that was quantifiable by flow cytometry (Figure
3.1A). By measuring each tracer bead concentration in the combined exit stream
of the microfluidic device (total flow = 16 µL/min for 5 min; channel wall shear
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Figure 3.2: A. Flow cytometry identification of the eight distinct particle peaks. B.
Comparison of relative percent of particles in the efflux of the flow device from 15
experiments using 5 different devices (bars are standard deviation, p >0.05 for all
compared to control).
rate = 222 sec−1 ), the flow rates were verified to be equal across the chambers
(Figure 3.1B). This uniformity across the channels was validated in 15 different
experiments using 5 different devices, thus confirming the designed intent that each
reactive interaction zone is under statistically indistinguishable bulk hemodynamics
and transport conditions. This characterization step, while somewhat mundane, is
absolutely crucial to the remainder of this Chapter of work, and for other studies
that utilize this design. While design principals and numerical simulations provide
excellent guidance for the development of more complex and useful device geometries
in this model system, careful, and perhaps painstakingly dull, experiments must be
performed in order to verify the assumptions and output of numerical models.
Since thrombus buildup reached heights of <20% of the chamber height for such
short distances, the pressure drop across an individual ∼250 µm long thrombus
would be small compared to the pressure drop across the entire length of a channel.
Thus, platelet accumulation at the collagen patch has a minimal effect on the flow
distributions within the system.
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3.4.2

IC50 for platelet P2-family inhibitors during thrombosis under flow

Three specific P2-family antagonists and apyrase were tested in a dose-response
mode to calculate effective IC50 ’s for collagen-induced platelet aggregate formation
inhibition, in the presence and absence of thrombin generation capability. In each
experiment, a total of eight simultaneously forming thrombi were imaged in real time
as shown in Figures 3.3 and 3.4. Fluorescenetly labeled platelets accumulate only
at the site of collagen exposure, with minimal non-specific upstream or downstream
adhesion. The collagen displays substantial surface coverage due to platelet adhesion to collagen within 1 min and subsequent secondary platelet accumulation via
platelet-platelet interactions over the 5 minutes as shown in Figure 3.4 with several
important results that are not immediately apparent. Theoretically, these receptor
antagonists should only have an effect on platelets that are recruited and activated
via ADP induced signaling via the P2Y1 receptor. Therefore, the initial adhesion
and activation events of platelets directly binding to and signaling from the collagen
exposure should remain unaffected. This is in fact the case, as the initial slopes of FI
vs time during the first 90 seconds of the experiment, the time during which a majority of the adhesion events are platelet-collagen interactions. This observation serves
as an internal control, and is only truly possible by the simultaneous measurement
of an untreated positive control group in addition to the experimental groups.
Determination of total surface fluorescence at 5 min allowed a determination
of the IC50 for each pharmacological agent as shown in Figure 3.5. The ability
to measure these dose response curves for platelet receptor antagonists under flow
with a direct comparison to untreated control samples on the same collagen surface
has not been performed before. Due to the nature of blood changing from the
moment it is removed from the flow forces and actively excreted factors from the
endothelium which keep platelets in a quiescent state in the body, running proper
control experiments is often very difficult. In addition, intra-donor variability can be
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Figure 3.3: Micrographs of fluorescently labeled platelets at a collagen patch at 0
(A), 1 (B), 2 (C), and 5 (D) minutes at the given concentrations of a P2Y1 inhibitor
MRS 2179.
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Figure 3.4: Kinetic trace of background corrected fluorescence at eight concentrations
of MRS 2179 measured simultaneously.
among the major drawbacks to using freshly isolated human tissue for hemostatic
experiments. However, this person to person difference can be an advantage with
a model system such as this, since each experiment is compared within itself. The
differences in platelet count, surface protein expression, soluble factor levels, and
thousands of other metrics that have been shown to affect platelet assays can be
accounted for, with the relative impact of pharmacological intervention determined
on a given day at a specific time. This is one of the main attractive features for
possible future development of these types of systems as diagnostic devices for pointof-care situations.
The P2Y1 and P2Y12 inhibitors displayed remarkably robust dose-dependent effects on limiting the accumulation of platelets at a localized collagen region. This
is in contrast to the P2X1 inhibitor which had no effect, as has been demonstrated
previously at comparable shear rates in the lower physiological regime [42]. The
thrombin generation in this system appears to be minimal, since there is no difference in the presence or absence of an irreversible thrombin inhibitor, as shown in
the near identical measurements shown in Table 3.2 and Figure 3.5. The ability to
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Figure 3.5: IC50 curves for the three pharmacological inhibitors and apyrase in the
absence (A, C, E, G) or presence (B, D, F, H) of thrombin inhibition.
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Table 3.2: IC50 values for the pharmacological inhibitors and apyrase (n = 4 different
donors, P >0.39 between CTI only and CTI/PPACK
Compound
P2Y1 (MRS 2179) [µM]
P2Y12 (2-MeSAMP) [µM]
P2X1 (NF 449) [µM]
Apyrase (U/mL)

CTI only
CTI and PPACK
0.171 ±0.093
0.227 ±0.098
2.619 ±0.994
2.497 ±0.700
NA
NA
NA
NA

run the number of experiments on the number of different donors for the range of
inhibitor concentrations is solely due to the minimal material requirements of the
microfluidic model system. Four interventions were measured at seven different concentrations for four different donors with the appropriate controls for five minutes
of flow under venous shear rates. If these experiments were to be performed in classical parallel plate flow chamber assays, over 5 L of donor blood would have been
required, in addition to over $7,000 for the labeling antibody alone, not to mention
significantly more inhibitor and labor requirements. However, if positive controls
were performed with each and every experiment, as were done in this study, the
costs and material requirements would be increased by another factor of two. While
the presence and role of blood derived tissue factor exposed on or accumulating at
collagen-induced platelet activation is still under intense investigation, the relatively
short experimental time (5 min) without exogenous tissue factor results in minimal
thrombin and fibrin generation in this model system as expected [79].
In contrast to small molecular P2-receptor antagonists, apyrase operates by a
different mechanisms in preventing platelet activation by nucleotide substrate by
enzymatic hydrolysis. In the microfluidic focal injury model, apyrase was unable to
prevent collagen-initiated platelet accumulation, even at extremely high levels (100
U/mL) of the enzyme. This lack of effect was not mediated by incubating the enzyme
with the blood sample for up to 10 min (results not shown).
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Figure 3.6: Apyrase activity confirmed by incubating 0.5 U/mL apyrase with 5 µM
ATP for 10 min prior to luciferase addition (n = 3, p <0.01 between ATP with
luciferase and ATP preincubated with apyrase and luciferase).
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Figure 3.7: Results of closed system approximating ADP release by collagen activated platelets and subsequent hydrolysis by varying concentrations of apyrase.
Enzyme activity was confirmed by reduction of ATP-mediated luciferase signal
as shown in Figure 3.6. The slight enhancement of platelet deposition at 10 U/mL
may be due to conversion of released ATP to ADP compared to the kinetically slower
reaction and weaker binding of ADP to apyrase compared to ATP.

3.4.3

Numerical simulation of apyrase-mediated ADP hydrolysis in open and closed systems

The closed system of an aggregometry cuvette was model using Equations 3.4, 3.5,
3.9, 3.10, 3.13, with the instantaneous ADP concentration at 2 min used to determine
dose dependence, as seen in Figure 3.7. In order to approximate the amelioration of
the ‘active cloud’ [47] of ADP generated at the site of platelet activation of apyrase,
average ADP concentration in a region 5 µm above the length of the reactive zone
were calculated using a finite element method coupled to a convective flow field. This
numerical exercise validates the practice of using relatively moderate concentrations
(between 0.5 and 3 U/mL) of apyrase while performing aggregometry studies to
ameliorate ADP and ATP receptor activation.
These calculations were made across a range of apyrase concentrations of 1×10−5
to 3×104 U/mL, with representative samples shown in Figure 3.8. The steadystate concentrations in the reactive zone were plotted as a function of bulk apyrase
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Figure 3.8: Results of open system approximating ADP release by collagen activated
platelets and subsequent hydrolysis by varying concentrations of apyrase.
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Figure 3.9: IC50 calculations for numerical simulations for both open (red squares)
and closed (blue circles) systems.

concentration, calculating an effective IC50 using Equation 3.1. Unlike the closed
system analogous to an aggregometry cuvette, where the control volume was drawn
around the entire experimental volume, the only region of interested in the open
system is that immediately above the active region. The reason for this is the focal
nature of the collagen exposure and the passivization of the remainder of the glass
surface and device walls. Since this model system is intended to investigate the effect
of these inhibitory treatments on localized injuries, it is presumed that endothelial
cells upstream and downstream of the injury site are not compromised, hence platelet
accumulation is limited to the site of injury.
The dose dependent behavior is shown in Figure 3.9. As shown, increasing the
apyrase concentration effectively abolished any ADP in the closed system at 1 U/mL,
the concentration which is most commonly used in aggregometry.
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The slight but reproducible increase in platelet accumulation under high (10, 30,
and 100 U/mL) apyrase concentrations observed in the experimental system was
hypothesized to be the result of preferential conversion of ATP to ADP by apyrase
at the location of the growing thrombus. There are two prevalent isozymes of the
apyrase enzyme, with relative ATPase:ADPase activity ratios of 12:1 and 1:1 [53],
with most apyrase reagents supplied as mixtures of the two. By running the numerical simulations with both pairs of binding and kinetic rate parameters, it was possible
to show that in both the closed and open systems, an apyrase-mediated increase in
ADP is generated due to preferential conversion of ATP released simultaneously
during platelet degranulation as shown in Figure 3.9.
The dose dependent behaviors are not sensitive to the flux imposed at the reactive
surface of the open system, which is important since literature estimates for the ADP
flux from a growing thrombus vary over four orders of magnitude [72, 5], indicating
that the phenomena is independent of the actual ADP flux at the surface as shown
in Figure 3.10.

3.5

Discussion

The 8-channel microfluidic focal injury model allows the rapid determination of the
effective concentration of anti-platelet and antithrombotic agents under flow conditions. By designing and fabricating a pair of microfluidic devices for patterning
collagen and perfusion with tight spatial control, this system is able to measure the
accumulation of fluorescent platelets at 8 independent sites of collagen exposure simultaneously. By dosing small volumes (90 µL) of whole blood from a single donor
with correspondingly small volumes (10 µL) of inhibitor, it is possible to generate a
full response curve from a single experiment. The dose response behavior observed
in this system for both 2-MeSAMP and MRS 2179 was similar to previously reported
data [14, 105, 9], implying that the inhibitors maintained their operational range in
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Figure 3.10: In the open system with unequal (A, closed symbols) and equal (B,
open symbols) ATP:ADP rate parameters, the dose dependence of apyrase mediated
ADP depletion is largely unaffected by flux over four orders of magnitude (high in
red squares, low in black triangles).
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spite of a more complex and rigorous experimental system.
The biochemical modes of action of the P2Y1 and P2Y12 inhibitors used in this
work are different from the family of compounds currently used as to inhibit the receptors as anti-platelet therapeutics (the thienopyridines). These compounds require
metabolism to turn the administered pro-drug into the active compound, which then
binds its target receptor irreversibly and prevents ligand binding and subsequent
G-protein signaling. This mode of action is in contrast to the reversible binding,
direct acting compounds used in this work (MRS 2179 and 2-MeSAMP) and next
generation therapies under investigation (ARC69931MX). The reversibility of the
compound interactions with the receptor may be a concern, as shown by lack of efficacy leading to the early termination of the ARC69931MX trial (ClinicalTrials.gov
identifier NCT00306162). However, the activity of MRS 2179 (IC50 200 nM) in this
system was comparable to the published Ki of 138 nM [9], while 2-MeSAMP required
a concentration approximately 10 fold higher than its calculated Kd (0.23 µM) [49]
for half-maximal effect in this assay (IC50 ∼ 2.5 µM), which could be accounted for
by the presence of a high affinity ADP binding site on platelets [46].
The inability of apyrase to prevent platelet accumulation at a collagen surface
and the corresponding numerical simulations of both open and closed systems have
several relevant and important implications. The mode of action of an enzymatic
degradation of receptor ligand in the bulk phase is fundamentally distinct from direct
receptor antagonism. By preincubation of small molecule inhibitors with the blood
sample, ample time is given for diffusion to, recognition of, and equilibration with
the antagonist’s given receptor, thereby disabling the ability of the receptor to bind
its ligand and signal. However, enzymatic degradation of ligand must occur in the
time between ligand exposure, in this case ADP release from dense granules upon
primary platelet activation, and receptor binding. In closed, well mixed systems,
such as aggregometry cuvettes, the ligand, enzyme, and receptor are all equally
distributed throughout the control volume. Under flow conditions where platelets
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accumulate to levels that are 10 to 50-fold greater than in normal whole blood,
apyrase is kinetically unable to degrade locally released ADP, even with convective
removal of ADP. The experiments and simulations were performed at relatively low
(210 sec−1 ) shear rates compared to the arterial vasculature, which is the targeted
region of action for anti-platelet agents. The slower flow rates, and correspondingly
low convective transport of ADP away from the growing thrombus, representing
higher agonist concentrations and a more rigorous test of compound potency.
Upon further investigation of the preferential hydrolysis of ATP to ADP for a
specific isozyme of apyrase, it was determined that local ADP concentrations, in the
presence of the right amount of apyrase, could actually be higher than in the absence
of apyrase.
While this is easily rectified by using an enzyme with, at the absolute minimum,
an equal affinity for both ATP and ADP, the effects of convection on the system still
dominate, as shown in Figure 3.11. The system modeled here only takes into account
the species released from platelets. It is well established that red blood cells are key
factors in regulating vascular tone, using ATP as one of the main mediators [25]. Red
cells can release very significant amounts of ATP, especially in hypoxic conditions,
upwards of 2×107 molecules per cell, leading to local ATP concentrations of over 160
µM. In this regard, red blood cells act as sources of ATP, which in the presence of
circulating apyrase, could lead to increased ADP concentrations at growing thrombi.
This analysis implies that dosing high concentrations of adenosine phosphatases
required to have an effect under flow conditions of could actually increase platelet
accumulation at the site of injury which was observed in this model system (at
apyrase concentrations of 10, 30, and 100 U/mL), putting individuals at risk for
atherothrombosis at higher risk for pathological clot formation.
However, the open system described in this work is fundamentally different from
classical aggregometry experiments. Rather than an isotropic release throughout
the control volume, the focal nature of the injury necessitates that ADP generation
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Figure 3.11: In the open system with unequal (A) and equal (B) ATP:ADP rate
parameters, the dose dependence of apyrase mediated ADP depletion is largely unaffected by flux over four orders of magnitude.
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is also localized to the growing thrombus site. While laminar flow is characteristic
of physiological conditions found in a large majority throughout the vasculature, it
necessarily is accompanied by poor radial mixing, especially of non-ionic molecular
species (MW >100 Da).

Da =

U ·L
V · cA

(3.14)

The competing phenomena of reaction and convective transport is characterized
in a dimensionless number typically used to describe chemical reactor efficiency,
called the Dämkohler number [11], defined by Equation 3.14, with U , L, V , and
cA representing characteristic reaction rate, length, velocity, and concentration respectively. As the Dämkohler number approaches infinity, the reaction approaches
completion as it would under no flow conditions (i.e. V → 0) within the interaction
zone. However, as the Dämkohler number approaches zero, convection dominates
the system meaning the reaction is minimal within the region of interest. In the experimental system and open system simulation, the Dämkohler number is 2×10−3 , or
close to zero. This is manifested in the fact that the simulation results suggest that
exceedingly high apyrase concentrations would be required to have an effect on the
local ADP concentration for a given flow profile. It is worthwhile to reiterate that
the experiments and simulations were performed at wall shear rates of 210 sec−1 ,
a relatively low physiological shear rate. Higher shear rates, and correspondingly
higher velocities, would only decrease the Dämkohler number and decrease the effect
of any bulk phase enzymatic based agonist depletion.
The simple dimensional analysis provided by the Dämkohler number leads to
several important clinical implications. This work indicates that enzyme-mediated
ligand removal for localized surface-mediated events occurring under bulk convective
transport will be limited, not due to enzyme specificity, but rather by the time required to react compared to convection away from the zone of interest. A number of
nucleotide phosphohydrolase therapies currently undergoing testing for diminishing
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ADP-induced excessive platelet accumulation in thrombotic pathologies have shown
early success in one of two major ways. The first is to use a model injury system
that includes an element of stasis, either an ischemic stroke model [84] or an ischemia/reperfusion thrombosis model [55]. While these in vivo model systems are
highly relevant, their intrinsic lack of blood flow at the site of injury necessarily
provides the soluble enzyme the time required to act, in contrast to injury models
in which blood flow is maintained. The second and newer approach is by which the
enzymatic domain of CD39 is covalently bound to a targeting moiety, hence allowing
local enzyme concentration to greatly increase compared to the bulk concentration
at the site of injury [19]. This surface-bound enzyme increases the residence time of
the enzyme at the active site, provide more enzymatic activity at the site of ADP
action.

3.6

Conclusions

In summary, this chapter has shown that a microfluidic focal injury model is capable of measuring the responsiveness of platelets to a set of inhibitors by measuring
changes in collagen-induced accumulation under flow. While inhibitors of the P2Y1
and P2Y12 receptors displayed dose-dependent efficacy, the P2X1 antagonist did not
have any effect in this model system. Similarly, the phosphohydrolase apyrase was
not able to reduce platelet accumulation by hydrolyzing ADP and preventing its
action on subsequent activation of additional platelets. Numerical simulations have
given us insight into why apyrase is able to function at moderate (1 U/mL) concentrations in aggregometry and other closed systems, however significantly higher
concentrations (1,000 U/mL) would be required for similar abolition of ADP induced platelet activation under single-pass flow conditions. In addition, the preferential hydrolysis of ATP to ADP by a non-specific apyrase can increase the local
ADP concentration to levels higher than in the absence of the enzyme, increasing
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platelet accumulation on a focal collagen region. This work represents a step towards
what could be a functional assay used to rapidly estimate a patient’s response to
anti-platelet therapy, prior to or during prophylactic treatment.
This Chapter has outlined how improvements in experimental throughput in
combination with simple finite element method mathematical modeling has help to
illuminate the potential issues with a therapy currently undergoing treatment. Two
aspects of this model system were crucial for this finding: namely the small material
requirements and the simultaneous experimentation. Large quantities of commercially available apyrase were required in order to obtain final concentrations of 100
U/mL in a small (∼100 µL) sample for these experiments. This would have been
completely cost prohibitive were it to be performed in a classical parallel plate flow
chamber, which would have required over $ 7,000 worth of fluorescent antibody and
over 5 L of donor blood, not to mention other materials requirements. Secondly, and
perhaps more importantly, the ability to repeatedly see relative increases in platelet
accumulation to simultaneously running control blood samples from the same donor
on the same collagen preparation was the critical step to investigating the enzyme
specificity. While integrated signals were noticeably different, the apparent accumulation during the experiment was only slight. The ability to compare multiple
repeats of the experimental condition to a simultaneous control were invaluable.
While these changes greatly increased the power of this model system over that
described in Chapter 2, it is important to note that the system used in this Chapter remains simplistic. The power of protein micropatterning and soft lithography
coupled with replicate molding is in the integration of more complex and realistic
surfaces and flow conditions, not simply straight channels and a collagen zone.
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Chapter 4
On the Impact of Secondary
Surface and Bulk Flow
Modifications in Thrombus
Formation
4.1

Abstract

The ultimate goal of ex vivo model system development is to provide the user with
control over as many of the experimental variables as possible, while including as
much of the complexity and realism of the in vivo situation. Realistically, this approach towards in vivo conditions has to occur gradually, and preferably modularly:
providing opportunities to increase the system complexity when it is desired, while
retaining the ability to revert back to simpler, perhaps more well established, system
operation modes. Hemostasis research is no different in that there is a continuum of
in vitro systems that are useful for the investigation into new aspects of platelet and
coagulation biology. The addition of a coagulation inhibitor, tissue factor, to the
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initial surface condition, and the manipulation of the flow history of a blood sample are two logical steps towards the recreation of the complex biological situation
of thrombosis. Significant engineering advances are required for the localization of
known amounts of active tissue factor on a surface in a repeatable and physiologically relevant way, the initial steps of which are investigated here. Furthermore, the
flexibility of soft lithographic techniques to form complex, yet physically relevant, geometries to mimic pathologies commonly encountered in diseased individuals allows
for the initial studies of the impact of shear exposure to thrombogenic potential. In
both cases, this work outlines both the advances and remaining hurdles that exist to
further develop model systems of thrombosis and hemostasis that being to approach
the complexity and richness of the their in vivo analogues, while maintaining the
control of in vitro experimental procedures.

4.2

Background

4.2.1

Tissue Factor

Tissue factor is a 41 kDa protein that is expressed in cells throughout the body,
with highest expression levels in the brain, the adventitial around blood vessels,
and skins cells [62]. While the importance of tissue factor in a proper hemostasis
response is important and will be discussed in more detail, there are other critical
signaling roles of tissue factor. The tissue factor knockout is an embryonic lethal
mutation, with incomplete blood vessel development [63]. The role of tissue factor
in vascular development and tone are linked to both its proteolytic cofactor activity
as it is in the extrinsic hemostatic cascade as shown in Figure 1.3, but also as an
important signaling molecule in the proper maintenance of blood vessels, the uterus,
the placenta and the heart [63].
The source of tissue factor during injury is currently still under investigation
and a controversial topic among researchers in the field. There are a large number
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of proposed sources of tissue factor in the vasculature: de novo synthesis [99] and
pre-formed exposure [83] in platelets, microparticles [34] as well as tissue factor
that is ubiquitously expressed in the subendothelial space [13]. In addition to the
physical source of the tissue factor protein, biochemical changes that are induced in
the protein are equally important to its activity. Some of the hypotheses that are
currently under investigation include tissue factor de-encryption by protein disulfide
isomerase [3] or negative phospholipid exposure [4].
Tissue factor is a transmembrane protein that requires a negatively charged phospholipid surface for the proper assembly and activity. Upon activation, platelets
exchange their lipid content from the inner membrane leaflet to the extracellular
side, providing phosphatidylserine for assembly. As platelets continue to accumulate
and activate within a growing thrombus, the surface for coagulation assembly and
propagation greatly expands, while platelets become physical barriers to convective
removal of activated species from the reaction zone. It is important to note that
only a few of the coagulation reactions require a negatively charged phospholipid
surface (as shown in the gray boxes in Figure 1.1), convective removal of products
dominates the reaction rates in almost all types of thrombus formation, as described
in Equation 3.14.
The role of tissue factor in in vitro, ex vivo, and in vivo injury model systems
remains under research and a source of controversy. Models of arterial thrombosis
stain positively for tissue factor during thrombus growth [31], with fibrin forming in
the injured area. While a significant fraction of the tissue factor in in vivo models
most likely is derived from activated endothelial cells and the vascular bed, including
smooth muscle cells [110]. In contrast, most ex vivo and in vitro flow experiments
do not incorporate exogenous tissue factor in the surface preparation. Those that do
either do use as the sole initiator [91], or in combination with other matrix proteins
[79, 80]. While these experiments have led to interesting and important realization
70

about tissue-factor driven coagulation under flow, the ability to investigate the longtime thrombin generation and clot formation is limited in these systems due to their
volume requirements. The microfluidic system used in this work provides the ability
to investigate the role of tissue factor in collagen-induced thrombosis under flow,
since relatively long (30 min) experiments can be performed repeatedly and with
reasonable (∼5 mL) blood volume requirements.

4.2.2

Von Willebrand Factor and effects of shear

Among the proteins involved in clot formation, von Willebrand Factor (vWF) is
the largest and perhaps most complicated in terms of production, release, function, signaling, and degradation. Originally formed in both endothelial cells and
megakaryoctes [29]. Upon synthesis, vWF undergoes a number of complicated posttranslational modifications, the final result of which is being packaged into granules
(Weibel-Palade bodies or α-granules in endothelial cells and platelets respectively).
These vesicles are exocytosed upon activation signals, leading to locally high concentrations of the protein, in addition to the ubiquitous circulating concentration of
approximately 10 µM in the blood plasma [2]. The advanced processing and packaging of vWF leads to a wide size distribution of multimers both within intracellular
stores and in the circulating species [60]. The protein assumes a mostly globular
structure while circulating in the blood stream, however previous work has shown
that upon either high amounts of shear stress or upon platelet tethering, these large
multimers can stretch out into a string-like form [76, 107]. The prevailing theory
is that vWF-mediated transient platelet adhesion is crucial at elevated shear rates,
where platelet collagen bonds are too slow to form and signal during the short interaction times in elevated flows, such as the arteriole system [115, 21].
There has been much work to date that describes the importance of vWF, from
its clinical origins when discovered in 1926 Erik von Willebrand in Finland, to the
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protein crystal structure of its platelet-interacting subunits [23]. By presenting protein domains that bind both to collagen repeats and proteins on the platelet surface,
specifically glycoprotein Ib (GPIb) and integrin αIIb β3 , multimers of vWF monomers
serve as potent potentiators of platelet accumulation. Several in vitro experimental
results describe the critical role of vWF in shear-induced platelet activation (SIPA),
whereby platelets undergoing a shear force in a cone-and-plate viscometer become
activated and aggregate together, mostly via vWF-GPIb interactions [82]. Recent
work has also indicated that the local shear conditions may be directly responsible for
platelet activation [73], although in a complicated and non-focal nature. However,
it is known that during the progression of coronary heart disease, atherosclerotic
plaques build up well into the luminal space of a diseased vessel, which can lead
to either complete blockage via a thrombotic event or simply vessel collapse [89].
Immediately prior to full vessel collapse, blockages of up to 98 % luminal crosssectional area have been reported, which results in local pathological shear rates of
up to 50,000 sec−1 [16, 90]. While these shear rates have induced SIPA in vitro, the
relatives times of pathological shear exposure in vivo and those required to activate
platelets or bind to collagen in vitro are separated by orders of magnitude (tens of
ms to tens of sec) [61].
A majority of the work done to investigate the behavior of platelets, vWF, and
collagen under high shear flows have been performed under uniform high shear across
a large surface coated either with collagen or vWF [97, 114, 85]. While these experimental conditions may approximate the dynamics of what would be considered
plaque failure at the throat of a stenosis, the inflexibility of flow chamber designs
has severely limited the ability of research to examine how the flow history of blood
affects its behavior when presented with an injury mimetic. Even very brief exposures to very high forces are proposed to have potentially significant effects on
thrombus formation [67]. Additionally, some of the signalling mechanisms within
platelets activated by binding of surface proteins to shear-exposed vWF domains
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can significantly alter the procoagulant and subsequent platelet recruitment activity
[69]. By beginning to parse out the effect of shear exposure and the effect of surfacemediated vWF accumulation under shear is an important aspect to understanding
the systemic effects of a high shear region within the vascular system.

4.3
4.3.1

Materials and Methods
Blood collection and labeling

Blood was obtained and labeled as described in Section 3.3.1.

4.3.2

Device fabrication, characterization, and validation

PDMS devices were fabricated, characterized, and validated as described in Sections
2.3.3 and 3.3.3.

4.3.3

Electron microscopy

In order to more closely investigate the aggregates formed during the experiments,
samples were imaged with a scanning electron microscope. After perfusion of blood
for the specified time through the device, the blood in the inlet reservoir was replaced
with fresh HBS. The flow rate was maintained for 1 min while the buffer cleared a
majority of the unbound red cells through the device. The inlet reservoir was then
filled with 1.6 % paraformaldehyde, then 2 % glutaraldehyde (Sigma-Aldrich, St.
Louis, MO) in HBS, and perfused for 5 min each. The flow was then stopped and
the thrombus allowed to fix in situ for at least 3 hr at room temperature. After
the incubation, the device was carefully removed from the glass slide, ensuring that
the thrombi formed remained intact and adhered to the glass surface. After device
removal, the thrombi were fixed in in the following order: A, A, A, B, A, A, A, with
‘A’ designating 0.2 M sodium cacodylate buffer (pH 7.0), and ‘B’ 2 % glutaraldehyde
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in HBS, each for 10 min at room temperature. The last fixative was left on the sample
overnight at 4°C. The following day, glass slides were scored to isolate the reactive
zone where the thrombi are formed. The small glass areas were then dehydrated in
the following percentage 100 % ethanol in 0.2 M sodium cacodylate for 10 min each:
50, 70, 80, 90, 100, 100. The dehydration was then finalized by incubating the sample
in 50:50, then 100:0 hexamethyldisilazane (HMDS, United Chemical Technologies
Inc., Bristol, PA) : 100 % ethanol for 15 min each. Samples were then immediately
mounted with double sided carbon tape on an aluminum stub (11 mm, Ted Pella,
Redding, CA). Samples were then sputter coated with platinum/palladium using a
sputter coater (Cressington Scientific Instruments Ltd., Watford, UK) for 35 sec at
an argon overpressure of 0.08 mbar, with a current between 25 and 30 mA. Samples
were imaged on a JEOL 7500 FEG-SEM (JEOL Ltd., Peabody, MA) in Gentle-Beam
(GB-H) mode, with a net accelerating voltage of 2 kV with a 2 kV sample bias at a
current of 10 µA in secondary electron imaging mode at a probe current of 7.

4.3.4

Tissue factor lipidation and activity assay

Tissue factor requires a negatively charged phospholipid surface for its activity. In
vivo, this surface is dependent upon platelet and endothelial cell activation and intracellular processes that flip phosphatidylserine (PS) from the inner to the outer
platelet membrane. In addition, when platelets are activated, they undergo radical shape changes, supplying significantly more surface area than a non-activated
platelet for surface mediated reactions to occur on. In order to capitalize on the variety of synthetic functionalized lipids available, recombinant human tissue factor was
relipidated into custom functionalized liposomes according to previously published
methods [74]. Briefly, lipid mixtures of the desired final molar ratio were mixed
well in chloroform, followed by drying to a lipid film under vacuum for at least 4
hours. After removal of the solvent, the film was rehydrated by incubating in HBS
overnight at 4 °C. Liposomes were formed by thorough vortexing of the rehydrated
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lipid film. The non-ionic lipid detergent 3-[(3-Cholamidopropyl)dimethylammonio]1-propanesulfonate (CHAPS, Pierce, Rockford, IL) was used to solubilized the liposomes which were mixed with purified recombinant human tissue factor (expressed
in S. frugiperda, EMD Biosciences, Gibbstown, NJ). The detergent was dialyzed
away by placing the solution in a 10 kDa cutoff membrane dialysis cartridge (Pierce,
Rockford, IL) and exchanging against three changes of 1 L HBS, allowing each to
equilibrate for 12 hours at 4 °C. Following dialysis, the relipidated protein was stored
at -20 °C until used.
The activity of the tissue factor was evaluated using a three component purified
system. Equal volumes of relipidated tissue factor was added to a 96 well plate containing varying amounts of activated Factor VII (FVIIa, Haematologic Technologies,
Essex Junction, VT) along with a fixed concentration of the fluorogenic substrate
Boc-Val-Pro-Arg-AMC (Bachem, Torrance, CA). Fluorescence cleavage of the substrate was monitored every minute for three hours on a fluorescence plate reader
(EnvisionII, Perkin Elmer, Waltham, MA). The change in fluorescence was calculated for each time point and best fit to a line. The slopes were then plotted as a
function of total VIIa concentration.

4.3.5

Tissue factor immobilization for controlled in vitro
thrombin generation

In order to localize tissue factor at the site of collagen exposure for focal thrombin production, a series of chemical linkages were employed. There are two design
goals for this section: specific targeting of the tissue factor bearing liposomes to the
collagen patch and retention of tissue factor activity when bound to the targeted surface. The first technique approach was to use streptavidin-coated beads as a physical
linker between the collagen surface and the liposomes. The streptavidin-biotin interaction is extremely specific and effectively irreversible with a dissociation constant
Kd ≈ 10−14 M. Superparamagnetic beads are commercially available, commonly
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used for the isolated of biotinylated gene products from cell lysates or releasates,
available in a range of sizes. For this work, 1.8 µm superparamagnetic streptavidincoated beads (Polysciences Inc., Warrington, PA) were used in conjunction with a
bench-top magnetic separator (Invitrogen, Carlsbad, CA). Biotinylated liposomes
were mixed in a 99:1 molar ratio with a biotinylated antibody (anti-collagen, Type
I, biotin conjugated, Chemicon/Millipore, Billerica, MA) and allowed to equilibrate.
Particles were then added and allowed to mix under slight agitation at room temperature for 30 min. After the liposomes containing the tissue factor and antibody
have equilibrated with the particles, the excess soluble agents are removed by three
cycles of magnetic separation and re-suspension in fresh buffer. The second linkage was using the same biotinylated antibody with a direct streptavidin linkage to
the biotinylated liposome, utilizing the multi-valency of the streptavidin molecule.
For those experiments used with a soluble streptavidin linker, fluorescently labeled
streptavidin (Streptavidin-Cy3 from Streptomyces avidinii, Sigma-Aldrich, St. Louis,
MO) was used.

4.3.6

Shear effects on thrombus formation

In order to investigate the results of a short exposure to pathologically high shear
rates, devices were designed and fabricated. Numerical simulations were performed
as previously described in Section 3.3.7, utilizing symmetry conditions at both the xy and x-z centerlines in order to increase grid density within the desired region. Grid
independence was confirmed again by Richardson extrapolation [86]. Fluorescentconjugated antibodies used to stain for the presence of adsorbed vWF (anti-von
Willebrand Factor (FITC), Abcam, Cambridge, MA) either to the collagen region
or within the formed thrombi. For experiments with platelet free plasma, etylenediaminetetraacetic acid disodium salt solution (EDTA, Sigma-Aldrich, St. Louis,
MO) was used to a final concentration of 5 mM to chelate calcium during phlebotomy, preventing both coagulation and platelet integrin activation. Whole blood
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was centrifuged at 2500 g for 15 min, and the supernatant (platelet poor plasma)
removed. That sample was subsequently centrifuged at 16,100 g for 15 min to pellet
any residual platelets or red blood cells, with the resulting supernatant considered
to be platelet free plasma (PFP).

4.4

Results

4.4.1

Tissue factor activity in custom functionalized liposomes

In order to verify the activity and determine the specific amount of active tissue
factor presented on the apical surface of the liposomes post-dialysis, a functional
assay was performed. The substrate Boc-Val-Pro-Arg-AMC was used, despite its
intention as a thrombin specific substrate. The substrate was converted by both
FVIIa and the tissue factor FVIIa (TF-VIIa) complex, but at different rates.
KM,1

T F + V IIa ←−→ T F · V IIa

KM,2

(4.1)

k

2
V IIa + V P R − AM C ←−→ V IIa · V P R − AM C −
→
V IIa + AM C

KM,3

(4.2)

k

3
T F ·V IIa+V P R−AM C ←−→ T F ·V IIa·V P R−AM C −
→
T F ·V IIa+AM C (4.3)

The reaction network is shown in Equations 4.1, 4.2, 4.3. Reaction progress is
monitored by measuring the fluorescence of the AMC group upon cleavage from the
peptide substrate.
This conversion is shown in Figure 4.1 and the cleavage rate increases linearly
with the FVIIa concentration as shown in Figure 4.2.
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Figure 4.1: Fluorescence traces of the cleavage of AMC from the peptidyl substrate
Boc-Val-Pro-Arg-AMC by a range of concentrations of purified FVIIa.

Figure 4.2: FVIIa concentration dependent substrate cleavage of fluorogenic substrate (n = 8).
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Figure 4.3: TF-catalyzed FVIIa-mediated substrate cleavage of fluorogenic substrate,
with blank liposomes at the same concentration (n = 8).

When the FVIIa enzyme is in the TF-VIIa complex assembled on the surface of a
phospholipid vesicle, this cleavage rate increases significantly, as shown in Figure 4.3.
The infection point, at approximately 0.5 nM of FVIIa, indicates the concentration of
tissue factor in the system, as explained by Equations 4.1, 4.2, 4.3, with KM,3 > KM,2
and k2 < k3 .

This effect was not due to the lipid from the tissue factor, as shown in Figure 4.4.
By examining the inflection point of the conversion rate with added FVIIa, it was
possible to estimate within a factor of two the active concentration of tissue factor
incorporated into the liposomes. This concentration corresponded to approximately
half of the molar concentration of molecular tissue factor introduced prior to dialysis.
This decrease of expected concentration is due to the equal probability of the tissue
factor protein incorporating into the membrane with its active surface on the apical
and basolateral surfaces of the liposome during formation.
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Figure 4.4: TF-catalyzed FVIIa-mediated substrate cleavage of fluorogenic substrate,
with blank liposomes at the same concentration shown in open circles with tissue
factor liposomes in filled circles (n = 8).

4.4.2

Tissue factor immobilization on beads for in vitro thrombin generation

Characterizing the amount of tissue factor immobilized on the streptavidin-coated
superparamagnetic particles was the first step in utilizing them for surface-initiated
thrombin generation. While it would have been ideal to use the same activity assay
used to characterize the free liposomes, the number of particles required for significant signal would be prohibitive even in the case of ideal liposome-particle binding.
In order to circumvent this issue, the self-amplification of thrombin production in
whole blood as the result of tissue factor initiation was used. A well-plate based
assay, using 10x diluted whole blood drawn into sodium citrate (to chelate calcium)
and CTI (to block contact-pathway-dependent FXIIa formation and subsequent FXase activity), was re-calcified after mixing with varying concentrations of either TF
bound to particles or in free liposomes. Thrombin formation was measured using
Boc-VPR-AMC cleavage at known kinetic rates. Thrombin formation was distilled
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Figure 4.5: Initiation time measurements for determining particle-bound tissue factor
concentrations. Conversion of 5 % of Boc-VPR-AMC was set to be the initiation
time (n = 8).
to an initiation time, or the time at which 5% of the substrate was cleaved.
The results of the initiation time experiments are shown in Figure 4.5. From this
data, it is possible to approximate the concentration of active tissue factor molecules
at 350 molecules per particle, or a tissue factor density of 35 molecules per µm2
of bead surface. This value is well within the range of published reports for active
tissue factor concentrations under flow [79]. It is interesting to note in Figure 4.5
that the inclusion of lipids without active tissue factor to the assay results in a slight,
yet statistically insignificant, decrease in initiation time. This is in concert with the
prevailing notion that negatively charged phospholipid surface is, to an extent, one
of the limiting reagents in this assay.
Once the particles were fully characterized, their ability to specifically bind to
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micropatterned collagen was evaluated. Soluble human type I collagen was allowed
to polymerize on a Sigmacote-treated glass slide for approximately 3 hr as described
in Sections 2.3.3 and 3.3.2. Following collagen formation, the patterning device was
rinsed with ∼100 µL of 0.5 % BSA in HBS. Loaded particles were then diluted to
approximately 107 particles/mL and allowed to fill the channel at a controlled flow
rate of 5 µL/min.
As can be seen in Figure 4.6, the particles co-localize with the collagen strip, but
there is uneven distribution of particles across the surface of the collagen. Secondly,
the particles tend not to adhere to the collagen as single, independent particles, but
rather as aggregates of various sizes. Adjustments in antibody:TF:particle ratios
were made in order to sample some of the available operating space to solve these
problems, however none was successful. Slight improvements in coating homogeneity
were accomplished by cycling bulk flow of particles on and off through the channel at
30 min intervals, essentially filling the channel space with particles, allowing them to
encounter and bind to the collagen. Alleviation of particle aggregation was attempted
by including low concentrations (0.1 to 1%) of a low molecular weight (2,000 Da)
poly(ethylene glycol) during lipid and antibody binding. This slightly mediated some
of the particle aggregate formation, but nonspecifically adsorbed to the collagen once
introduced to the channel, quenching its biological affinity and activation of platelets
when exposed under whole blood flow.
The activity of the tissue factor immobilized on targeted beads on a collagen
surface was examined in several ways. The first attempts to flow recalcified plasma
over the beads at a low flow rate were unsuccessful. There are a number of reasons
that would explain this, namely the relatively small amount of lipid surface area
for coagulation complex assemblies, specifically extrinsic prothrombinase (XaVa).
Attempts were made to visualize both fibrin formation and cleavage of Boc-VPRACM by epifluorescence, but neither readout revealed any activity. The next attempt
was to perfuse whole blood that had been treated with CTI only to inhibit the
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Figure 4.6: Micrograph of streptavidin-coated superparamagnetic beads linked to
tissue-factor containing biotinylated liposomes and biotinylated anti-collagen antibody localized on micropatterned human type I collagen. The left channel shows
the fluorescently labeled collagen, with differential interference contrast micrograph
of the beads on the right at three magnifications (10X, 20X, and 40X from top to
bottom).
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Figure 4.7: Confocal reconstructions of thrombi formed on collagen and tissue factor
coated particles. Flow is from from to back with 10 µm grids.
contact pathway over the TF beads on the collagen surface. Platelet adhesion to
the collagen was minimally affected when monitored with AlexaFluor 647 anti-CD41
antibody signal compared with a purely collagen surface.
As can be seen in Figure 4.7, even in the presence of fibrin polymerization inhibitor Gly-Pro-Arg-Pro (GPRP), the platelet thrombus volume is higher in the sample with thrombin production allowed compared to the thrombin inhibitor PPACK.
The fibrin forming capability of the tissue factor on the particles is shown in Figure 4.8. Clearly the tissue factor on the beads has initiated enough of the coagulation
cascade to produce significant amounts of thrombin and therefore form fibrin fibers.
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Figure 4.8: Scanning electron micrograph of fibrin formed around tissue factor coated
particle, flow from left to right.
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However, these experimental results were difficult to duplicate and necessarily hard
to quantify.

4.4.3

Direct tissue factor immobilization on collagen for in
vitro thrombin generation

Due to the problematic nature of getting even tissue factor bearing bead distribution
on the collagen surface, a second more simplistic approach was used. Capitalizing
again on the specificity and irreversibility of the streptavidin-biotin bond, a layer-bylayer approach was taken. After the collagen film was formed, sequential solutions
containing biotinylated anti-collagen antibody (various dilutions), soluble streptavidin (10 µg/mL), and biotinylated relipidated tissue factor (∼ 2 nM) separated by
rinses in 0.5 % BSA in HBS were performed. In order to investigate the effectiveness
of using the bulk antibody concentration to control the extent of surface coverage
with the streptavidin, and subsequently the tissue factor, a titration of the antibody
was performed using the fluorescent streptavidin binding as the readout.
As is shown in Figure 4.9, there is a marked decrease in fluorescence at the
collagen region with increasing antibody dilution, indicating that controlling the
bulk concentration gives a handle on the amount of antibody coverage. The activity
of the streptavidin-linked tissue factor was evaluated by perfusing human blood over
a collagen strip coated with antibody diluted at 1:1000 in 0.5% BSA in HBS, which
appeared in Figure 4.9 to give an relatively high (approximately 5 % surface coverage)
coating.
As is seen in Figure 4.10, the thrombi formed with active tissue factor at the
surface in addition to collagen grow to significantly larger size. However, the most
striking difference between thrombi formed on collagen alone and those formed with
surface-immobilized tissue factor is the stability of those thrombi. It is clear that by
20 min, all of the thrombi had embolized from the collagen region. This behavior
was observed even at antibody dilutions of 1:105 , or less than 1 % surface coverage
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Figure 4.9: Micrographs of Cy3-streptavidin bound to biotinylated anti-collagen
antibody on a collagen surface, exhibiting dose-dependent fluorescence, with the
ratio of 0.5 % BSA in HBS to antibody indicated by the number in the upper left
of each image (scale bar is 50 µm).
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Figure 4.10: Micrographs of thrombi forming on a tissue factor coated collagen
surface. Flow is from bottom to top at an average wall shear rate of 210 sec−1 (scale
bar is 500 µm, CTI human whole blood).
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Figure 4.11: A. CAD design of stenosis device, with 500 µm wide inlet and outlet
regions surrounding a 10 µm wide stenosis region, in this case 2.5 mm long. B.
Differential interference contrast micrograph of the inlet section of a finished device.
of the lipid.

4.4.4

Characterization of stenosis mimetic device

To investigate the extent to which flow history has on the adsorption of vWF and
the accumulation of platelets on collagen, a set of microfluidic devices were designed
as stenosis mimetics.
The design that accomplished this is shown in Figure 4.11. Similar designs were
fabricated with stenosis lengths of 1, 2.5, and 5 mm, each of which had a width of
10 µm with inlet and outlet widths of 500 µm. Among the key design criteria of
this device was to ensure that the flow profiles through the inlet and outlet regions
of the stenosis did not result in flow separation and recirculation zones. While
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these complicated fluid dynamics may occur in vivo, especially in the case of stent
placement for percutaneous coronary intervention [50], the first approximation of
atherosclerotic blockages are relatively gradual increases and decreases in effective
luminal cross-section, hence the assumption of fully-developed, laminar (at least
pre- and post-stenosis) flow. In order to confirm the desired gentle inlet and outlet
of the stenosis mimetic, a series of computational fluid dynamics simulations were
performed.
As seen in Figure 4.12A, the fluid dynamics simulations indicate that streamlines
enter and exit the stenosis region with smoothed, continuous traces. Figure 4.12B
indicates that the shear rate in the stenosis region decreases rapidly at the expansion
zone back to that found in a non-stenosed device of the same (500 µm) width within
500 µm of the stenosis exit. To confirm the indications of the mathematical modeling,
fluorescent 1.8 µm beads were perfused through the fabricated devices at a controlled
flow rate.
The indication of Figure 4.13 is that the stream lines predicted in the calculations
are in fact observed in the actual device when operating under conditions to be used
in experimentation. After confirming the ideality of the inlet and outlet regions of
the stenosis zone, the device was used to investigate the effect of flow history on
thrombus formation. This was performed by utilizing flow channels that included a
5 mm long stenosis region (10 µm width) with 500 µm wide inlet and outlet regions,
and a channel on the same physical device of a constant 500 µm width. The devices
used were fabricated to a height of 53 µm. Platelets were labeled as before (3.3.1)
while visualization of vWF was attempted using the FITC-conjugated antibody. CTI
and PPACK treated human whole blood was perfused at a flow rate of 10 µL/min,
corresponding to an average wall shear rate of 1,000 sec−1 in the inlet and outlet
zones and a shear rate of approximately 50,000 sec−1 in the stenosis region across a
500 µm wide collagen patch of human type I collagen.
As is seen in Figure 4.14, the morphology and kinetics of thrombus formation
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Figure 4.12: A. Streamline approximations of the inlet and outlet regions of the
stenosis mimetic device. B. Local shear rate (surface) and velocity field (red arrows)
at the outlet of the stenosis region.
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Figure 4.13: Long exposure (5 sec) micrographs of fluorescent beads entering and
exiting the stenosis region in a device depicted in Figure 4.11 (2 µL/min flow rate,
scale bar is 100 µm).
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Figure 4.14: Time course of platelet and vWF accumulation at the collagen zone of
human whole blood either passing through a stenosis region or not. Flow is from
top to bottom and scale bar is 100 µm, CTI/PPACK human whole blood.
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are relatively different between the same donor blood, on the same collagen, with
the only difference being a short, yet very severe, exposure to shear, comparable to
what may be found in a severely stenosed coronary artery.

4.5

Discussion

As presented in Chapters 2 and 3, measuring the accumulation of platelets on a
collagen surface through a straight channel can lead to novel and interesting insights
into the biology of platelet receptors and receptor antagonists. However, there is
still a significant gap between the complicated exposure of subendothelial proteins
and matrix components that are exposed upon injury. In fact, the composition and
type of subendothelium differ throughout the vasculature, depending on the size,
location, and purpose of the vessel, as one would expect for such a dynamic and widefunctioning mass contacting system. Additionally, imperfections and geometrical
complications of the vascular system are frequently overlooked when investigating
the already complicated dynamics of platelet accumulation and thrombus formation.
This work begins to delve into the complex yet more realistic arena of injury mimetic
systems.

4.5.1

Role of surface-bound tissue factor in ex vivo thrombus formation

The ability to immobilize tissue factor on the surface to initiate coagulation has
been a challenge in the field of hemostasis research for years. Recently, a number of
advances have been made, however each with their own set of limitations. Contact
protein arrays [79] have been used to show the dose-dependence of tissue factor to
significant fibrin formation under whole blood flow. Other microfluidic methods
in conjunction with sophisticated lipid patterning techniques [51, 52, 91, 102] to
investigate some of the transport issues that are relevant to active species formation
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and transport during clot formation. Other mathematical models have been used
to interrogate some of the unknown reaction dynamics that are characteristic of
thrombin formation during coagulation processes [39, 28, 27]. Other work has focused
on using endothelial cells, treated with a molecule to induce an injury-like response
[57], relying on the endothelial cells themselves to release the appropriate soluble
factors and express the proper surface antigens to stimulate platelet adhesion and
activation.
The most trusted and comprehensive model system of thrombosis to date is the
laser-induced cremaster muscle murine model [26, 30]. It had not been until late
2009 that the extent and type of this injury was well understood in terms of what
area of subendothelium, what depth into the subendothelial layer, and the resulting
thrombus composition and size were with respect to the intensity of the laser injury
[43]. While the injury model has been revolutionary in its ability to focally and
reliably create similar injuries within the arterioles or venuoles of living mice, this is
the first study to truly examine the implications of this type of injury. The authors
found that several endothelial cells were completely ablated by the injury, with some
of the injuries resulting in tissue destruction several tens of microns into the media
of the blood vessel. This injury model system involves the formation of thrombin
and the generation of fibrin at the injured vessel wall, as shown in both the original
work and multiple subsequent studies. This thrombin generation is mostly likely due
to tissue factor exposure to the flowing blood due to the removal of the endothelial
cell barrier, and possibly subsequent additions by various blood-borne sources. The
important aspect with respect to this work is the fact that not only is tissue factor
exposed at a finite location, but also that numerous additional matrix proteins,
not the least important collagen, are simultaneously exposed in conjunction with
endothelial cell, and in some cases smooth muscle cell, lysate.
In terms of the relevance of the work presented here, there are a number of important differences when compared with previous ex vivo model systems. Firstly,
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the work utilizing a purified lipid surface, on which the active tissue factor is assembled and allowed to react with either plasma or purified components lacks a
number of important variables. Without a collagen substrate, the only activator
of platelets would be thrombin formed from the reactive surface, hence deposition
and subsequent feedback of platelet activation is severely dampened. Secondly, the
use of platelet rich plasma removes the largest cellular fraction of the blood in the
red blood cells, which are critical for proper hemodynamic conditions within the
vessel, causing numerous alterations to local platelet concentrations and applying
forces to other cells during flow. Working with endothelial cell layers may prove to
be the next generation of thrombosis model systems, especially with the constant
advances of on-chip cell culture and angiogenic practices to essentially grow blood
vessels under controlled conditions, on which subsequent experiments could be performed [116]. However, the current technology and robustness of forming proper
and repeatable blood vessels in vitro are limiting both the realism and reliability
of results from such experiments. Perhaps the most realistic model system to date
has been the inclusion of tissue factor to other matrix proteins such as collagen and
vWF during contact microarray experiments while performed in a parallel plate flow
chamber. By allowing human whole blood to encounter a number of proteins which
they would be exposed to upon injury in a relatively focal region remains the best
realization of a tissue factor-including thrombosis model.
This work has approached a system with a key advantage over that of any other
work. Specifically, the ability to specifically measure and control the amount of tissue factor on the surface of a focal exposure to blood in addition to collagen. While
the work of [79] attempted to measure concentration effects, the reported concentrations were given in bulk soluble tissue factor concentrations without any knowledge
of the amount or extent of active protein remaining on the surface after initial rinsing steps. The advantage with a pseudo layer-by-layer approach to building a tissue
factor surface on top of collagen is the ability to control the precise amount of tissue
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factor with known activity on the surface, by controlling bead density, antibody coverage, and tissue factor:lipid ratio during relipidation. This control is of the utmost
importance when working with a system with such a tight and strong operating
threshold such as tissue factor. This switch-like behavior is paramount for its in vivo
activity, either thrombin must be formed in order to stem blood loss from an injury,
or it must not to prevent excessive clot formation and subsequent stasis. The main
issue that has arisen in this work with tissue factor on a collagen surface has been
the ability of the thrombi formed on the surface to remain. There are a number of
potential causes for this, the first of which is simply a lack of completeness of the
model system. As noted, the electron microscopy of the injured vessels from the
in vivo model system show a large section of subendothelium exposed, not simply
a region of type I collagen with some purified lipid and protein intermixed. The
embolization of the thrombi formed during this work always showed a failure at the
collagen-platelet interface. Most likely, this failure was due to a significant fraction
of the collagen region being covered by lipid, necessary for the tissue factor’s activity. The mechanical failure of the thrombi to remain adherent may also be due
to a necessary evil of ex vivo hemostasis research, that is the contact pathway. In
order to prevent coagulation due to the contact of blood with negatively charged
plastic surfaces that it is necessarily in contact with up to the point of perfusion over
the collagen strip, inhibitors (CTI) must be used. Recent work has shown that the
contact pathway plays a significant role in the attenuation and magnitude of thrombin generation in a collagen-induced injury system [109]. This may be important in
continuing thrombin generation to create fully activated and adherent platelets on
an otherwise slightly ‘slippery’ lipid-rich collagen surface.

4.5.2

Effects of shear history on thrombus formation

The second aspect of this work that begins to capitalize on the flexibility and scale
of microfluidics is the experimentation with stenotic flow models. It is well known
97

that the narrowing of arteries, specifically in the coronary vasculature and the blood
vessels within the brain, complete blockages of which lead to heart attacks and strokes
respectively, are the largest cause of death within the developed world. Perhaps
the reason that atherosclerosis as a disease in particular is a promising target for
prevention is that it is a chronic condition that occurs as plaques build up over
years of improper diet, lack of exercise, and in some cases genetic mutations with
faulty or non-existing gene products. This gradual progression of the disease often
remains unnoticed until some catastrophic event, either a vessel collapse or plaque
rupture and thrombosis, which can either block the blood flow at the site of rupture,
or send large and deadly thrombi throughout the vasculature resulting in a range
of pathologies. Currently, there are no good means of early detection for patients
at risk for atherosclerosis, as imaging technologies continue to attempt to visualize
differences in flow without the high collateral damage associated with invasive scope
procedures.
The work described with investigating the effects of exposing whole blood to
pathologically high shear conditions for very finite periods of time is very promising
on a number of accounts. Firstly, it speaks to the very fast mechanisms by which
blood can change its state.
Figure 4.15 shows that even 2 µm from the wall, the fluid is moving at approximately half of the maximum velocity, indicating that platelets and plasma in the
red cell depleted outer layer experience the high shear in a 5 mm stenosis at 50,000
sec−1 for less than 200 ms. This high stress zone is quickly dissipated back out into
a physiologically normal 1,000 sec−1 where it encounters the injury mimetic collagen
strip. What is not immediately obvious from Figure 4.14 is that the thrombi formed
after the shear exposure were very prone to thrombosis, similar to those shown in
the tissue factor work. The causes are not directly comparable, as no tissue factor
or lipid was present in the collagen that was encountered by blood after the stenosis.
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Figure 4.15: A plot of the velocity in the stenosis region across the z-midline.

The platelet aggregates formed on the same collagen preparation without being subjected to the high shear zone formed stable thrombi analogous to control aggregates
formed throughout the work.
The implications and potential value of these initial findings are very interesting. Firstly, the cause of the alteration due to shear exposure is of interest. Total
transit time post-stenosis is less than 1 sec, indicating that whatever mechanism is
leading to altered platelet deposition must occur rapidly, either through a series of
messengers with platelets or red cell mediated ATP release. However, a potentially
more fundamental and important phenomena may be working on the large vWF
multimers found circulating in the blood stream. The soluble protein is constantly
in equilibrium with GPIb receptors on the platelet surface while circulating throughout the blood stream with rapid on and off events which prevent further aggregation
in unneeded situations. Assuming that this model is correct, as the blood enters
the stenosis region, a small but finite fraction of vWF is bound to platelets. If the
literature models are correct in that the vWF-GPIb bond is in fact a catch bond,
then the high stresses applied during transgression across the stenosis region would
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increase the stability of the bond. This high stress on the globular vWF molecule
could open up the conformation into an extended, much more hemostatically active
molecule. In effect, the platelet transiently bound to the molecule would be acting
in a manner similar to a sail, greatly increasing the effective area for shear forces
to pull on the condensed quaternary structure of quiescent vWF. This elongated
vWF molecule then under goes some relaxation once it exits the stenosis region,
however since the collagen region in this work is in close proximity to the outlet of
the stenosis, some fraction of the molecules remain in their elongated conformation.
This increased vWF deposition on the collagen surface then mediates much more
platelet-surface interaction than the collagen alone, leading to larger thrombus formation, and perhaps due to steric coverage of collagen sites required for full signaling
and platelet activation, less stable thrombi.

If exposure, even for a very brief amount of time, to high shear can cause a
conformational change for vWF into an elongated form, there are several interesting
avenues to be pursued. Most striking would be the use of elongated vWF multimers as markers of atherosclerosis progression and even location. By sampling
the amount and relative state of vWF multimers circulating in a patient’s blood
stream from different locations throughout the body (immediately before and after
athero-prone zones such as the aortic arch or coronary arteries), it may be possible
to determine both the extent and the relative location of dangerous atherosclerotic
lesions in a manner much less invasive than current imaging modalities provide. As
a biomaker of overall vascular tone, elongated vWF levels may aid those at higher
risk for atherosclerosis, or those with known cases of atherosclerosis, to monitor the
progression or regression of the disease with a simple blood-based analysis.
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4.6

Conclusions

This chapter has outlined some of the secondary alterations to both the initial (surface) and inlet (flow history) conditions of the blood that encounters a reactive
surface. While this system is far from ideal and the in vivo model systems from
which it is modeled, the strengths of continual improvement and iterative design
principals are touched on. Improvements in injury mimetic, with the introduction
of a tissue factor source that is both repeatable and directly titratable remains the
logical and critical next step in building a thrombosis model system that can incorporate both the coagulation cascade and platelet activation simultaneously but
in balance with the other. In addition, using known physiological and pathological
conditions as design inspiration in concert with the flexible and precise fabrication
method that soft lithography and replicate molding offers, it is possible to extract
new biological behavior from systems that may be occurring and naturally reporting
on flow conditions throughout the body. Investigating the wide range of secondary
surface and flow interactions provides a rich area for further work with thrombosis
in microfluidic model systems.

4.7

Future Work

Among the most immediate goals for furthering the understanding of secondary modifications to both the injury mimetic surface and the flow geometry, the successful
development of a repeatable and controllable tissue factor source remains the most
important. A lack of thorough understanding about the specific location, distribution, and form of tissue factor exposed to blood during an injury even has not aided,
but does not serve as an excuse for the unsuccessful development of a surface bound
tissue factor model injury. Perhaps the single most difficult obstacle to overcome
is the functional necessity of tissue factor to be incorporated into a lipid membrane
bilayer for biological activity. While other groups have continued to experiment with
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new and exciting formulations of active tissue factor [68], the ability to create a robust thrombosis model that includes surface immobilized tissue factor remains a goal
of the hemostasis community. The simplicity of protein micropatterning lends itself
to this problem, insofar as any series of fluid phase species are easily introduced to
the surface in series or parallel in order for proper assembly and retention of hemostatic activity for all components involved, specifically collagen signaling and tissue
factor activity.
The initial worked laid out for the use of stenosis-like flow patterns to investigate
the potential shear-induced opening of vWF molecules into extended confirmation
likewise has many avenues for further investigation. Initial attempts were made to
visualize extended vWF multimers in platelet free or platelet rich plasma, however
with the current detection systems no strands were visualized. Previous work has
shown that vWF strands can assemble on collagen [7], however the difference with
this work is that the vWF in our system only experiences high shear rates while inside
the stenosis region while the capture occurs at a lower shear rate. Direct visualization
of these extended confirmation vWF multimers would be the first step towards their
utilization as potential biomarkers of atherosclerotic progress. A second interesting
arena for further study would be in the stability of thrombi formed after exposure to
a shear insult. Sorting out the exact mechanism of the mechanical instability when
compared to unsheared blood may further lead down avenues that explain thrombi
vulnerabilities in individuals.
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